

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

BMJ Open

Implementation of a virtual community of practice to promote the empowerment of middle-aged people with multimorbidity: Study protocol of a randomized controlled trial.

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-084937
Article Type:	Protocol
Date Submitted by the Author:	01-Feb-2024
Complete List of Authors:	Campillejo, Alba; Community of Madrid Madrid Health Service, Foundation for Biosanitary Research and Innovation in Primary Care Gefaell-Larrondo, Ileana; Community of Madrid Madrid Health Service, Foundation for Biosanitary Research and Innovation in Primary Care Ramos-García, Vanesa; Canary Islands Health Service, Canary Islands Health Research Institute Foundation Koatz, Débora; Autonomous University of Barcelona, Avedis Donabedian Research Institute Foundation Santos-Álvarez, Anthea; Canary Islands Health Service, Canary Islands Health Research Institute Foundation Barrio-Cortes, Jaime; Community of Madrid Madrid Health Service, Foundation for Biosanitary Research and Innovation in Primary Care Gómez-Rueda, Sara; Community of Madrid Madrid Health Service, Gregorio Marañón Research Institute Cifuentes, Patricia; Community of Madrid Ministry of Health, University Hospital of Alcorcón Company-Sancho, Consuelo; Canary Islands Health Service, General Directorate of Ublic Health Domínguez-Coello, Santiago; Canary Islands Health Service, La Laguna Health Care Center - Family and Community Care teaching unit García-García, Francisco Javier; Canary Islands Health Service, Quality Care Unit - Nuestra Señora de La Candelaria University Hospital (HUNSC) Garrido-Elustondo, Sofía; Comunidad de Madrid Consejeria de Sanidad, Centre Family and Community Care Teaching Multiprofessional Unit González de León, Beatriz; Canary Islands Health Service, Tenerife Primary Care Management Ramón-Vazquez, José; Canary Islands Health Service, Tenerife Primary Care Management Martín, Candelaria; Hospital Universitario de Canarias, Internal Medicine Department Suárez-Fernández, Carmen; Community of Madrid Madrid Health Service, La Princesa Hospital Vicente-Rabaneda, Esther F.; Community of Madrid Madrid Health Service, La Princesa Hospital Vicente-Rabaneda, Esther F.; Community of Madrid Madrid Health Service, La Princesa Hospital

1	
2	
3	
4	
5	
6	
7	
, 8	
8 9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
20	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
30 37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
50	
51	
52 53	
54	
55	
56	
57	
58	
59	
60	

SCHOLARONE[™] Manuscripts

2
3
4
5
6
7
/
8
9
10
11
12
13
14
15
16
17
18
19
20
21
าา
22 23
23
24 25
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39 40
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
55 56
50 57
58
59
60

1

2

3

TITLE

TITLE PAGE

- Implementation of a virtual community of practice to promote the empowerment of middle-4 5 aged people with multimorbidity: Study protocol of a randomized controlled trial. 6 7 **AUTHORS AND AFFILIATIONS** Alba Campillejo-García^{1*}, Ileana Gefaell-Larrondo^{1,2*}, Vanesa Ramos-García^{2,3*}, Débora 8 Koatz^{2,4}*, Anthea Santos-Álvarez³, Jaime Barrio-Cortes^{1,2,5,6}, Sara Gómez-Rueda⁵, Amaia 9 Calderón⁷, Patricia Cifuentes⁸, M^a Consuelo Company-Sancho⁹, Santiago Domínguez-10 Coello¹⁰, Francisco Javier García-García¹¹, Sofía Garrido-Elustondo¹², Beatriz González de 11 12 León¹³, José Ramón-Vazquez¹³, M^a Candelaria Martín-González¹⁴, Carmen Suárez-Fernández¹⁵, Pedro Parra-Caballero¹⁵, Esther F. Vicente-Rabaneda¹⁵ Patricia Quiroga-Colina¹⁵, 13 Ana Belén Ramírez-Puerta¹⁶, Marta Ruíz-López¹⁷, María Eugenia Tello-Bernabé^{2,18}, Estrella 14 15 Sánchez-Gamborino-Del-Río¹⁹, Beatriz Ugalde-Abiega²⁰, Helena Vall-Roqué^{2,4}, Andrea Duarte-Díaz³, Analía Abt-Sacks³, Aránzazu Hernández-Yumar³, Alezandra Torrres-Castaño³, 16 Yolanda Álvarez-Pérez³, Christiane Muth²¹, Marjan van den Akker²², Victor M. Montori²³, 17 Carola Orrego^{2,4**}, Lilisbeth Perestelo-Pérez^{2,24**}, Ana Isabel González-González^{2,5,25**} 18 19 20 ¹ Fundación para la Investigación e Innovación Biosanitaria en Atención Primaria, Madrid (FIIBAP), Spain 21 ² Red de Investigación de Cronicidad en Atención Primaria y Promoción para la Salud (RICAPPS), Spain 22 ³ Canary Islands Health Research Institute Foundation, Tenerife, Spain 23 ⁴ Avedis Donabedian Research Institute (FAD), Universidad Autónoma de Barcelona, Spain 24 ⁵ Gregorio Marañón Research Institute (IiSGM), Madrid, Spain
- 25 ⁶ Universidad Camilo José Cela, Madrid, Spain
- ⁷ Karolinska Institutet, Stockholm, Sweden
- ⁸ University Hospital of Alcorcón, Madrid, Spain

BMJ Open

2		
3 4 5 6	28	⁹ Dirección General de Salud Pública, Santa Cruz de Tenerife, Spain
	29	¹⁰ Centro de salud de La Victoria - Unidad docente de Atención Familiar y Comunitaria, Santa Cruz de Tenerife, Spain
7	30	¹¹ Hospital Universitario Nuestra Señora de La Candelaria (HUNSC)- Unidad de Calidad Asistencial, Santa Cruz de
8 9	31	Tenerife, Spain
10 11 12 13 14	32	¹² Unidad Docente Multiprofesional de Atención Familiar y Comunitaria Sureste. Unidad de Apoyo a la Investigación.
	33	Gerencia de Atención Primaria. Madrid, Spain
	34	¹³ Gerencia de Atención Primaria de Tenerife, Canary Islands, Spain
15 16	35	¹⁴ Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
17 18	36	¹⁵ Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain
19 20	37	¹⁶ Technical Directorate of Project Integration and Control, Gerencia de Atención Primaria, Madrid, Spain
21 22	38	¹⁷ Centro de Salud Vicente Muzas, Madrid, Spain
23	39	¹⁸ Centro de Salud El Espinillo, Madrid, Spain
24 25	40	¹⁹ Centro de Salud Rafael Alberti, Madrid, Spain
26 27	41	²⁰ Hospital Universitario Ramón y Cajal, Madrid, Spain
28 29	42	²¹ Department of General Practice and Family Medicine, Medical School OWL, University Bielefeld, Bielefeld,
30 31	43	Germany.
32 33	44	²² Institute of General Practice, Goethe University, Frankfurt am Main, Germany.
34	45	²³ Knowledge and Evaluation Research Unit, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
35 36	46	²⁴ Evaluation Unit (SESCS). Canary Islands Health Service (SCS), Tenerife, Spain
37 38	47	²⁵ Innovation & International Projects Unit, Subdirección General de Investigación y Documentación, Viceconsejería
39 40 41 42 43	48	de Sanidad de la Comunidad de Madrid, Spain
	49	
	50	
44 45	51	*Authors contributed equally
46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	52	** Senior authors contributed equally
	53	
	54	CORRESPONDING AUTHOR
	55	Ana Isabel González González. Address: C. de la Aduana, 29, Consejería de Sanidad, 28013
	56	Madrid. email: aisabel.gonzalezg@salud.madrid.org. Phone: +34 646107832.

57 ABSTRACT

58 Introduction

Empowering people living with multimorbidity (multiple chronic conditions) to gain greater confidence in managing their health can enhance their guality of life. Education focused on self-management is a key tool for fostering patient empowerment and is mostly provided on an individual basis. Virtual Communities of Practice (VCoP) present a unique opportunity for online education in chronic condition self-management within a social context. This research aims to evaluate the effectiveness/cost-effectiveness of individualized, online self-management education compared to VCoP among middle-aged individuals living with multiple chronic conditions.

67 Methods and analysis

People aged 30-60, living with >2 chronic conditions, and receiving care in primary care centers and outpatient hospital-based clinics in Madrid and Canary Islands will enroll in an 18-month parallel-design, blinded (intervention assessment and data analysts), pragmatic (adhering to the intention-to-treat principle), individually randomized trial. The trial will compare two 12-month web-based educational offers of identical content; one delivered individually (control) and the other with online social interaction (VCoP, intervention). Using repeated measures mixed linear models, with the patient as random effect and allocation groups and time per group as fixed effects, we will estimate between-arm differences in the change in Patient Activation Measure (PAM) from baseline to 12 months (primary endpoint), including measurements at 6- and 18-months follow-up. Other outcomes will include measures of depression and anxiety, treatment burden, quality of life. In addition to a process evaluation of the VCoP, we will conduct an economic evaluation estimating the relative cost-effectiveness of the VCoP from the perspectives of both the National Health System and the Community.

3 4 5	81
6 7	82
8 9	83
10 11	84
12 13 14	85
	85
49 50	
51 52	
53	
54 55	
56	
57	
58 59	

60

Ethics and Dissemination

82 The trial was approved by Clinical Research Ethics Committees of Gregorio Marañón University Hospital in Madrid/Nuestra Señora Candelaria University Hospital in Santa Cruz 83 84 de Tenerife. The results will be disseminated through workshops, policy briefs, peer-reviewed nal c. 85 publications, local/international conferences.

86 Trial registration: ClinicalTrials.gov. NCT06046326

2 3 4 5	87	ST	RENGTHS AND LIMITATIONS OF THIS STUDY	
6 7	88	Strengths		
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26	89	•	Pragmatic, multicenter design enhances the generalizability of the findings.	
	90	•	Blinded assessment and data analysis reduce potential bias.	
	91	•	Inclusion of both a control and intervention group allows for effective comparative	
	92		analysis.	
	93	•	Comprehensive outcome measures, including patient activation, mental health, and	
	94		quality of life.	
	95	•	Longitudinal follow-up (18 months) provides insights into the sustained effects of the	
	96		interventions.	
27 28	97			
29 30 31 32 33 34 35 36 37 38 39 40	98	Li	mitations	
	99	٠	Limited to participants with internet access and digital literacy, which may affect the	
	100		representativeness.	
	101	•	Participation may be influenced by the willingness and ability of patients to engage in	
	102		online communities.	
41 42 43	103	•	The study focuses on a specific age group (30-60 years), which may limit applicability to	
43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	104		other age groups.	
	105	•	The intervention's success relies heavily on active participation in the Virtual Community	
	106		of Practice, which might vary among participants.	
	107	•	The study is geographically limited to primary care centers and outpatient clinics in	
	108		Madrid and the Canary Islands, which may affect generalizability.	

BMJ Open

109 INTRODUCTION

Multimorbidity is defined as the simultaneous presence of two or more chronic conditions in the same individual (1). Multimorbidity is becoming increasingly prevalent globally (2). While the prevalence of multimorbidity tends to rise with age (2), it is worth noting that more than 50% of individuals living with multiple chronic diseases are under the age of 65 (3-5).

Irrespective of age, individuals with multimorbidity tend to have a lower quality of life (6), use more healthcare services (7), and die younger (8) than people living with no or one chronic condition. However, how multimorbidity affects daily life may differ between middle-aged and older people.

It is in middle age when most chronic diseases first manifest. For middle-aged individuals with multimorbidity, the challenge lies in juggling the work of self-management with professional careers, childcare, eldercare, and leisure (9). Healthcare research has not adequately addressed the consequences of multimorbidity, in terms of an individual's capacity for self-care and the significant disruptions to family life, leisure, and community and professional commitments (10,11). Comprehensive, patient-centered strategies to address both medical and psychosocial aspects of care are urgently needed for middle-aged adults living with multimorbidity (12).

Empowerment is the process by which individuals gain control over managing the conditions of their daily life. Empowered individuals take actions to enhance their quality of life and possess the necessary knowledge, skills, attitudes, and self-perception to adapt their behavior and collaborate with others when required to achieve optimal well-being (13). There is a need for effective interventions that promote empowerment, self-confidence, self-esteem, and the ability to cope with the profound implications of multiple chronic diseases.

BMJ Open

According to Wenger et al. (14), a Community of Practice (CoP) is a group of individuals engaged in a common activity who develop a shared identity, deepen their knowledge, and expand their experiences in a particular field through ongoing interactions that strengthen their relationships. A group of people sharing the common condition of multimorbidity may benefit from an intervention where they can interact, exchange knowledge, resources, information, and receive mutual and professional support.

137 Virtual Communities of Practice (VCoP) offer widespread access to information and 138 opportunities for interaction among people facing similar situations, which is particularly 139 valuable for individuals with chronic conditions. Key benefits encompass receiving and 140 providing information, offering social support, boosting patient optimism, improving coping 141 skills, brightening mood, reducing anxiety, and managing stress more effectively (15).

143 METHODS AND ANALYSIS

144 Aim

The main objective of this study is to assess the effectiveness and cost-effectiveness of two online self-management programs for chronic diseases. The first is delivered through a VCoP, fostering a community-based approach (intervention), while the second is provided on an individual basis (control). Other secondary objectives will be taken into account.

review

149 Trial design

150 We will conduct an 18-month, pragmatic, multicenter, parallel, randomized controlled trial.151 See Additional file 1 for SPIRIT checklist.

⁸ 152 **Study setting**

Page 9 of 59

1

BMJ Open

2 3	153	Both groups will receive the intervention online as an add-on to their usual care at primary care
4 5	155	Both groups will receive the intervention online as an add-on to their usual care at primary care
6 7	154	practices and outpatient hospital-based clinics in Madrid and the Canary Islands, Spain.
8 9 10 11 12 13 14 15 16 17 18	155	Eligibility criteria and study population
	156	Patients aged 30-60 and diagnosed with two or more chronic conditions will be identified by
	157	their healthcare providers (primary care and hospital physicians and nurses) and proposed to
	158	be screened by the research team for the following eligibility criteria:
19 20	159	Inclusion Criteria
21 22	160	1. Age 30 - 60 years.
23 24 25	161	2. Documentation of at least two chronic diseases in the electronic medical record (EMR)
26 27	162	at the time of inclusion.
28 29 30 31 32	163	3. Access to the internet at home or via a smartphone.
	164	4. Ability to meet the study requirements [e.g., digital literacy questionnaire (Additional
33 34	165	file shows this in more details)].
35 36	166	5. Signed, written, informed consent.
37 38 30	167	Exclusion Criteria
39 40 41	168	1. Institutionalized individuals.
42 43	169	2. Receiving Palliative care.
44 45 46	170	3. Telephone/email contact information missing from clinic databases.
47 48 49	171	Recruitment and Implementation Strategies for Health Care Providers in Madrid and
49 50 51 52 53 54 55 56 57	172	Canary Islands.
	173	Recruitment Process
	174	Health care providers (HCPs) from Madrid and the Canary Islands will be invited to participate
58 59 60	175	in recruiting subjects for the study. To facilitate this process, the research team will conduct

BMJ Open

informative sessions with HCPs, including nurses and physicians from outpatient clinics and
primary care centers. These sessions will focus on detailing the project's objectives, outlining
specific recruitment guidelines, and describing the responsibilities involved. Interested HCPs
will then approach eligible patients, based on predefined inclusion criteria, to introduce them
to the study's aims and requirements.

181 <u>Patient Engagement and Information Dissemination</u>

Patients expressing interest in the study will be contacted by a member of the researcher team. This step involves providing comprehensive information about the study, addressing any queries, and assessing the patients' familiarity with computer and internet usage. Following this, patients will gain access to a specialized web platform, designed exclusively for this project. This platform houses the informed consent document (see Additional file 3), which participants are required to understand and sign before proceeding. Subsequently, participants will complete baseline questionnaires, after which they will receive a one-year access to their assigned implementation strategy. For data management the patient ID will be anonymized. The study's flow-chart can be found in Figure 1.

191 <u>Implementation Strategies Overview</u>

To define the interventions, we used the taxonomy of self-management interventions forchronic diseases developed by Orrego et al. (16):

- 194 1) Intervention Group "e-mpoderaT" Platform:
 - Platform Features: A gamified Virtual Community of Practice (VCoP), hosted on a Web 2.0 platform, will encourage the sharing of experiences and knowledge through collective learning (17). The platform will provide diverse educational and interactive

Page 11 of 59

BMJ Open

1		
2		
3 4	198	content, including forums, readings, resources, videos, games, and virtual sessions, all
5 6 7	199	aimed at enhancing self-care and promoting knowledge exchange.
7 8 9	200	• Customization and Support: Tailored to address the unique needs of people with
10 11	201	multimorbidity, this intervention will be co-created with patients and HCPs, leading to
12 13	202	the development of a "Patient Journey Map". A healthcare professional experienced in
14 15	203	facilitating patient groups will moderate the VCoP, ensuring active engagement,
16 17 18	204	addressing queries, and fostering communication with a multidisciplinary team of
19 20	205	experts, including general practitioners, cardiologists, psychologists, and nutritionists.
21 22	206	• Educational Focus: The content emphasizes patient empowerment dimensions like
23 24	207	health competence, behavioral change, symptom monitoring, and shared decision-
25 26 27	208	making, aligning with European guidelines for managing chronic diseases (17).
28 29	209	2) Control Group – Standard Care with Educational Access:
30 31	210	• Usual Care and Educational Resources: Participants in the control group will continue
32 33 34 35 36	211	receiving standard care in line with local guidelines. Additionally, they will have access
	212	to a self-administered platform featuring the same educational content as the VCoP,
37 38	213	minus the interactive and engagement components.
39 40		
41 42	214	Table 1 summarizes the implementation strategy. Description of materials and outcome measures
43 44 45	215	Description of materials and outcome measures
46 47	216	Primary outcome
48 49	210	
50 51	217	The primary outcome will be the level of patient activation, assessed using the Patient
52 53 54	218	Activation Measure (PAM) questionnaire (18). This questionnaire consists of 13 items that
55 56	219	evaluate knowledge, skills, and confidence for self-care in patients with chronic conditions.
57 58	220	Responses are measured on a Likert 1-4-point scale, resulting in a total score ranging from 0
59 60	221	to 100, with 100 indicating the highest level of patient activation. The Spanish-translated

BMJ Open

version has been validated in patients with chronic diseases and exhibits good validity and
reliability properties (19). The e-mpoderaT research team has previously employed this
questionnaire in their studies (e-mpodera (20) and e-mpodera2 (21)).

225 <u>Secondary outcomes</u>

Depression: The Patient Health Questionnaire-9 (PHQ-9) (22) will be used to detect depression, characterize its severity (23), and support follow-up (24). Validated in Spanish (25), it consists of 9 items that assess the presence of depressive symptoms in the last 2 weeks. Each item has a severity index: 0 = "never", 1 = "some days", 2 = "more than half the days" and 3 = "almost every day". A score between 0-4 indicates no depressive symptoms, 5-9 mild depressive symptoms, 10-14 moderate depressive symptoms, 15-19 moderately-severe depressive symptoms, and 20-27 severe depressive symptoms.

Anxiety: The self-administered Hospital Anxiety and Depression Scale HADS-A subscale
(26) is a 7-item questionnaire, validated in Spanish, and used in primary care (27- 29).
Items are scored from 0 to 3, with a score of 8 indicating possible and >10 probable anxiety
with good specificity and predictive value (30).

Treatment burden: Based on the self-administered Treatment Burden Questionnaire - TBQ
 (31). A 10-item version was validated in primary care of the UK in patients with
 multimorbidity (32). It uses a Likert scale that ranges from 0 (not difficult / does not apply)
 to 4 (extremely difficult) to assess the burden related to taking medication, self-care,
 medical appointments, and the need for organization. We will translate and adapt the MTB
 Questionnaire using the forward and back-translation procedure.

Health-related quality of life (HRQoL): We will assess this construct using the self administered EQ-5D-5L (33) validated in Spanish and used in primary care (34). It enables

Page 13 of 59

1 2 BMJ Open

3 4	245	the calculation of Quality-Adjusted Life Years (QALYs). The EQ-5D-5L descriptive
5 6	246	system comprises five dimensions (mobility, personal care, daily activities,
7 8 9	247	pain/discomfort, and anxiety/depression).
10 11 12	248	Explanatory and adjustment variables
13 14 15	249	• Sociodemographic: Age (years), gender, nationality, whether they live in Madrid or
16 17	250	Canarias, marital status (married/partner, single, separated, divorced, widowed), number of
18 19	251	living children, whether they have caregiving duties for parents (yes/no), educational level
20 21 22	252	(incomplete primary studies, complete primary studies, secondary education, university
23 24	253	studies or equivalent), and current occupation (i.e., unemployed, employed, self-employed,
25 26	254	sick leave, another situation).
27 28	255	• <i>Morbidity</i> : Number and description of concomitant chronic diseases. This information will
29 30		
31 32	256	be collected by collaborating professionals coinciding with the baseline evaluation of each
33 34	257	patient. An additional file of the O'Halloran list shows this in more detail (See Additional
35 36 37	258	file 4) (35).
37 38 39	259	• <i>Treatment</i> : We will record the quantity and details of medications prescribed for long-term
40 41		
42 43	260	(i.e., at least three months), continuous use for each patient. This information will be
44 45	261	meticulously collected by our team of collaborating HCPs at the time of each patient's
46 47	262	baseline assessment, ensuring accurate and comprehensive medication data.
48 49	263	• Use of resources: primary care (PC) visits, visits to the emergency department, visits to
50 51	264	specialists, number of hospitalizations, lengths of stay.
52 53	-	
54 55	265	• <i>Use of VCoP</i> : VCoP use data will be collected through the platform database.
56 57	266	• Unintended consequences of the interventions will be monitored along the duration of the
58 59 60	267	study (36).
00	201	Study (30).

268 See table 2 for more details.

269 <u>Timeline</u>

The primary outcome of our study (PAM), will be evaluated over a period of 12 months, starting from baseline. To ensure a thorough understanding of the PAM's progression, we will also conduct additional assessments at 6 and 18 months. Secondary outcome measures will be collected before the start of the VCoP intervention and at 6, 12 and 18 months. This information is shown with more details in Figure 2.

275 Data monitoring

The data will be monitored by the research team throughout the research process. Special attention will be paid to their quality and their correct collection. Primary analyzes will be conducted following completion of the 6-, 12-, and 18-month assessment questionnaires.

279 Randomization and blinding

STATA 17.0 software will generate a random sequence and will be used by an investigator to
allocate participants after they have been enrolled and provided written consent. The
intervention allocation will be blinded to participants, clinicians, and data analysts.

283 Statistical analysis

Sociodemographic and clinical baseline variables of both groups will be analyzed by descriptive methods according to the type of variable (mean [standard deviation (SD)], median [range], n [%]). The VCoP effect on the primary and secondary outcomes will be examined by means of repeated measures mixed linear models, with the intervention, time-point (0, 6, 12 and 18 months) and their interaction as fixed effects (along with other potential covariates), random intercepts for patients and clinicians, and unstructured covariance to account for Page 15 of 59

BMJ Open

within-subject correlations. We will also analyze the three-way interaction intervention × time × center, since usual care could vary between centers, leading to differential intervention effects. We expect to recruit enough clinicians to allow their inclusion in the model as a random intercept, but we will perform a sensitivity analysis as well as excluding this component. Between-group differences at each time-point will be compared by means of Wald's χ^2 test. We will perform the analyses on an intention-to-treat basis (a sensitivity analysis on the per-protocol population will also be performed). Multiple imputation will be used for missing data, if applicable (Markov Chain Monte Carlo multivariate imputation algorithm, with 10 imputations per variable). Analyses will be carried out with the statistical software R V.4.0.2 (http://www.R-project.org/).

300 Sample size

The necessary number of patients to detect, through independent means tests, a mean difference of 4 points (SD = 10) in the PAM questionnaire (18), between the intervention and control group, performing individual randomization, is 100 patients per arm. For this calculation, an alpha error of 0.05 and a power of 80% are assumed. This size is increased by the estimate of 20% loss, making a total of 240 patients.

306 Patient and public involvement

This protocol was developed without patient or public involvement. A group of middle-aged
patients with multimorbidity will actively participate in a content-design previous stage using
a co-creation methodology with virtual activities.

311 ETHICS AND DISSEMINATION

312 Informed consent (Additional file 3) will be obtained from each participant before313 randomization. The project has been approved by the local Ethics Committees of each

BMJ Open

participating Autonomous Community: Clinical Research Ethics Committee of Gregorio Marañón University Hospital in Madrid (PI22/01124) and Nuestra Señora de Candelaria University Hospital in Santa Cruz de Tenerife (CHUNSC 2023 06). Patients will be personally informed by their physicians or nurses about the study and the possibility to participate during a programmed consultation. They will receive written information of the proposed research project, regarding its aims, the duration of their involvement, the expected benefits for them and the procedures involved in the participation. Recruiters will emphasize that enrollment in the study is voluntary, that participants can withdraw at any moment of the project, and that any decision they take in this respect will have no bearing on the medical care received. Once patients have signed the written informed consent, a researcher from the 'e-mpoderaT' team will contact them via phone and/or email to provide further information along with the necessary data (username and password) to login into the online platform. Additionally, recruiters will highlight that information generated by the study will be published, but no identification details will be divulged. Patients and healthcare professionals will be informed of whom to contact in case of any query, and research staff will be available to answer questions. We will prepare presentations to disseminate the study findings to healthcare stakeholders and patients, and at relevant national and international conferences. We aim to publish the results of the trial in peer-reviewed journals and try to grant public access to the full manuscripts.

334 DISCUSSION

335 The e-mpoderaT project will experimentally test two strategies: 1) an innovative learning
336 intervention based on a VCoP for patient empowerment, for which the literature lacks
337 experimental evaluations; and 2) an individual, self-administered education, without any kind

Page 17 of 59

BMJ Open

of interaction among participants. VCoPs can enhance communication between VCoP members in different geographic locations and even from different time zones. However, participation rate can be low, as similar experiences have shown (20); that is why we will include the active role of a community manager, who will engage participants, answer questions, and provide support and a multidisciplinary team of researchers will focus on designing content and developing strategies for the VCoP. The e-mpoderaT platform will automatically send weekly emails as reminders and a gamified competitive score system to boost participation. Participation in both groups will require a minimum level of digital literacy; therefore, the results would not be generalized to all patients. Patients belonging to the control group and intervention group will receive different types of self-management support depending on the healthcare centers where their usual care is provided.

This project aims to demonstrate that the strategy involving the VCoP, where participants can interact and provide mutual support, proves to be a better tool than the other strategy, just receiving online self-administrated educational content, to help middle-aged individuals with two or more chronic diseases because they would have greater activation and involvement in managing their health, thus becoming more empowered, with less depression and anxiety, and a reduced burden of treatment. They would improve their health-related quality of life and have a lower need for healthcare resources, such as hospital admissions and emergency room visits.

TRIAL STATUS

The recruitment of patients in each region will start in January-February 2024. The estimated end date of the recruitment for this study is June 2024. This information is shown in more detail in Figure 3.

REFERENCES

362 1. Van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: what's in a
363 name? A review of literature. Eur J Gen Pract. 1996 Jan 11;2(2):65 -70.

364 2. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications
 365 for health care, research, and medical education: A cross-sectional study. Lancet.
 366 2012;380(9836):37 -43.

367 3. Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. Prevalence, determinants and patterns of
368 multimorbidity in primary care: a systematic review of observational studies. PLoS One.
369 2014;9(7):e102149.

370 4. Prados-Torres A, Calderón-Larrañaga A, Hancco-Saavedra J, et al. Multimorbidity patterns:
 ²⁶ 371 a systematic review. J Clin Epidemiol. 2014;67(3):254 -66.

372 5. Nicholson K, Terry AL, Fortin M, et al. Prevalence, characteristics, and patterns of patients
373 with multimorbidity in primary care: a retrospective cohort analysis in Canada. Br J Gen Pract.
374 2019 Sep;69(686):e647 -56.

375 6. N'Goran A, Déruaz A, Haller DM, et al. Comparing the self-perceived quality of life of
376 multimorbid patients and the general population using the EQ-5D-3L. Liu C, editor. PLoS One.
377 2017 Dec 19;12(12):e0188499.

378 7. Hopman P, Heins MJ, Rijken M, Schellevis FG. Health care utilization of patients with
 379 multiple chronic diseases in The Netherlands: Differences and underlying factors. Eur J Intern
 380 Med. 2015 Apr;26(3):190 -6.

381 8. Willadsen T, Siersma V, Nicolaisdóttir D, et al. Multimorbidity and mortality: A 15-year
382 longitudinal registry-based nationwide Danish population study. J Comorbidity. 2018 Jan
383 1;8(1):2235042X1880406.

⁶ 384 9. Ko D, Bratzke LC, Roberts T. Self-management assessment in multiple chronic conditions:

^o 385 A narrative review of literature. Int J Nurs Stud. 2018 Jul;83:83 -90.

Page 19 of 59

1 2

BMJ Open

- 3 4	
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 20 21 22 23 24 25 26 27 28 9 30 132 34 35 37 38 39	
7 8	
9 10 11	
12 13	
14 15	
16 17	
18 19	
20 21 22	
22 23 24	
25 26	
27 28	
29 30	
31 32 33	,
34 35	
36 37	
38 39	
40 41	
42 43 44	
45 46	
47 48	
49 50	
51 52 53	
54 55	
56 57	
58 59 60	
UU	

386 10. Lachman ME, Teshale S, Agrigoroaei S. Midlife as a pivotal period in the life course. Int J
387 Behav Dev. 2015 Jan 14;39(1):20 -31.

388 11. Leppin A, Montori V, Gionfriddo M. Minimally Disruptive Medicine: A Pragmatically
389 Comprehensive Model for Delivering Care to Patients with Multiple Chronic Conditions.
390 Healthcare. 2015 Jan 29;3(1):50 -63.

391 12. Dinh TS, Brünn R, Schwarz C, Brueckle M-S, Dieckelmann M, González González AI, et
 392 al. How do middle-aged patients and their healthcare providers manage multimorbidity?
 393 Results of a qualitative study. PLoS One. 2023;18(8):e0291065.

394 13. EMPATHiE Consortium. EMPATHiE, empowering patients in the management of chronic
 395 diseases. Final Summary Report. 2014.

- 396 14. Wenger E. Communities of Practice and Social Learning Systems. Organization.
 397 2000;7:225.
- 398 15. Rodgers S, Chen Q. Internet Community Group Participation: Psychosocial Benefits for
 399 Women with Breast Cancer. J Comput Commun. 2005 Jul;10(4):00 -00.

400 16. Orrego C, Ballester M, Heymans M, Camus E, Groene O, Niño de Guzman E, et al. Talking
401 the same language on patient empowerment: Development and content validation of a
402 taxonomy of self-management interventions for chronic conditions. Health Expect.
403 2021;24(5):1626–38. Available from: https://pubmed.ncbi.nlm.nih.gov/34252259/

404 17. Mosen DM, Schmittdiel J, Hibbard J, Sobel D, Remmers C, Bellows J. Is Patient Activation
 405 Associated With Outcomes of Care for Adults With Chronic Conditions? J Ambul Care Manag.
 406 2007;30(1):21 -9.

407 18. Hibbard JH, Greene J, Overton V. Patients with lower activation associated with higher
408 costs; delivery systems should know their patients' "scores". Health Aff (Millwood) [Internet].
409 2013 Feb;32(2):216 -22.

19. Moreno-Chico C, González-de Paz L, Monforte-Royo C, et al. Adaptation to European

 Spanish and psychometric properties of the PAM 13 in patients with chronic diseases. Fam Pract. 2017 Oct 1;34(5):627 -34. 20.- Orrego C, Perestelo-Pérez L, González-González AI, Ballester-Santiago M, Koatz D, Pacheco-Huergo V, et al. A virtual community of practice to improve primary health care professionals' attitudes toward patient empowerment (e-MPODERA): A cluster randomized trial. Ann Fam Med. 2022;20(3):204–10. Available from: https://pubmed.ncbi.nlm.nih.gov/35606139/ 21.- Koatz D, Torres Castaño A, Ramos García V, Vall Roqué H, Toledo Chávarri A, Cifuentes Pérez P, et al. A Virtual Community of Practice (VCoP) for people with ischemic heart disease: the implementation process. Int J Integr Care. 2022 Nov 4;22(S3):404. Available from: https://www.ijic.org/article/10.5334/ijic.ICIC22208/ 22. Spitzer RL. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999 Nov 10;282(18):1737. 23. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med [Internet]. 2001 Sep;16(9):606 -13. 24. Löwe B, Kroenke K, Herzog W, et al. Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). J Affect Disord [Internet]. 2004;81(1):61 -6. 25. Diez C, Rangil T, Sanchez L, et al. Validation and Utility of the Patient Health Questionnaire in Diagnosing Mental Disorders in 1003 General Hospital Spanish Inpatients. Psychosom Med. 2001;63(4):679 -86.

BMJ Open

3 4	433	26. Quintana JM, Padierna A, Esteban C, et al. Evaluation of the psychometric characteristics
5 6	434	of the Spanish version of the Hospital Anxiety and Depression Scale. Acta Psychiatr Scand.
7 8 9	435	2003 Mar;107(3):216 -21.
9 10 11	436	27. Herrero MJ, Blanch J, Peri JM, De Pablo J, Pintor L, Bulbena A. A validation study of the
12 13	437	hospital anxiety and depression scale (HADS) in a Spanish population. Gen Hosp Psychiatry.
14 15 16	438	2003 Jul;25(4):277 -83.
17 18	439	28. Terol-Cantero MC, Cabrera-Perona V, Martín-Aragón M. Revisión de estudios de la Escala
19 20	440	de Ansiedad y Depresión Hospitalaria (HAD) en muestras españolas. An Psicol. 2015 Apr
21 22 22	441	25;31(2):494.
23 24 25	442	29. Moryś JM, Bellwon J, Adamczyk K, et al. Depression and anxiety in patients with coronary
26 27	443	artery disease, measured by means of self-report measures and clinician-rated instrument.
28 29	444	Kardiol Pol. 2016;74:53 -60.
30 31 32	445	30. Bunevicius A, Staniute M, Brozaitiene J, Pop VJ, Neverauskas J, Bunevicius R. Screening
33 34	446	for anxiety disorders in patients with coronary artery disease. Health Qual Life Outcomes.
35 36	447	2013;11(1):37.
37 38 39	448	31. Tran V-T, Harrington M, Montori VM, et al. Adaptation and validation of the Treatment
39 40 41	449	Burden Questionnaire (TBQ) in English using an internet platform. BMC Med [Internet]. 2014
42 43	450	Dec 2;12(1):109.
44 45 46 47 48 49 50 51 52	451	32. Duncan P, Murphy M, Man M-S, Chaplin K, Gaunt D, Salisbury C. Development and
	452	validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ). BMJ Open.
	453	2020;8(4):e019413. Available from: https://bmjopen.bmj.com/content/8/4/e019413
	454	33. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and
53 54 55	455	preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011
56 57 58 59 60	456	Dec 9;20(10):1727 -36.

BMJ Open

3 4	457	34. Herdman M, Badia X, Berra S. El EuroQol-5D: una alternativa sencilla para la medición
5 6 7	458	de la calidad de vida relacionada con la salud en atención primaria. Atención Primaria.
7 8 9	459	2001;28(6):425 -9.31.
10 11	460	35. O'Halloran J, Miller GC, Britt H. Defining chronic conditions for primary care with ICPC-
12 13	461	2. Family Practice [Internet]. 2004 Aug 1;21(4):381–6. Available from:
14 15 16	462	https://academic.oup.com/fampra/article/21/4/381/518015
17 18	463	36. Ziebland S, Hyde E, Powell J. Power, paradox and pessimism: On the unintended
19 20 21	464	consequences of digital health technologies in primary care. Soc Sci Med.
21 22 23	465	2021;289(114419):114419. Available from:
24 25	466	https://www.sciencedirect.com/science/article/pii/S0277953621007516
26 27 28	467	
20 29 30 31	468	DECLARATIONS
32 33 34	469	Contributors
35 36 37	470	All the authors have contributed to the design of this study. All the authors will contribute to
38 39 40	471	every step of the trial and will also contribute to the dissemination strategy.
41 42 43	472	Funding
44 45	473	This work was supported by Instituto de Salud Carlos III (ISCIII), grant number PI22/01124
46 47 48	474	and PI22/00691 and co-funded by the European Union. Funding has been provided as well
49 50	475	from the RICORS, code RD21/0016/00028 (Redes de Investigación Cooperativa Orientadas a
51 52 53	476	Resultados en Salud) networks. The funders have no role in the study design.
54 55 56	477	Consent for publication
57 58 59 60	478	Informed consent will be provided to all the participants (Additional file 3).

1 2		
3 4 5	479	Availability of data and materials
6 7	480	To maintain participants confidentiality, all information will be stored with anonymized
8 9 10	481	identification code (ID code) numbers. All data will be stored on an electronic database
10 11 12	482	management system located on a secure server with password-controlled access provided for
13 14	483	research data collection. The Research Ethics Committees, the representatives of the Health
15 16 17	484	Authority in matters of inspection and the personnel authorized by the Promoter, may only
18 19	485	access to check personal data, clinical study procedures and compliance with the rules of good
20 21	486	clinical practice (always maintaining the confidentiality of information). Data will be available
22 23 24	487	for any audit process.
25 26 27	488	Competing interests
28 29 30	489	The authors declare no conflict of interest.
31 32 33	490	Acknowledgements
34 35 36	491	Avedis Donabedian Research Institute has been actively engaged in this area of research right
37 38	492	from the beginning. We sincerely appreciate their immense efforts and support, as this research
39 40 41	493	would not be possible without their valuable contributions.
42 43 44	494	Word count
45 46 47	495	2724
48 49 50 51 52 53 54 55 56 57 58 59 60	496	

Table 1. Implementation strategy.


INTERVENTION	INTERVENTION GROUP	ACTIVE CONTROL
COMPONENTS	"Virtual Community of Practice"	"Self-administered education"
Provisioning and support methods	Provision of information Skills training Emotional support Proposal of objectives and action plans Training in self-monitoring of symptoms and monitoring of healthy behaviors Using reminders Social support by peers and professionals (key to the intervention)	Provision of information Using reminders
Type of encounters	Support sessions	Self-administered intervention
Support modality	Remote (web-based)	Remote (web-based)
Type of platform	Web platform compatible with mobile devices	Web platform compatible with mobile devices
Type of communication	Synchronous (webinar-type activities, virtual meetings) and asynchronous (web)	Asynchronous (web)
Recipients	In a group	Individual
Type of providers interacting with patients	Professionals in primary and specialized care medicine, nursing, psychology.	There is no interaction with patients.
Setting	Primary care patients	Primary care patients
Content topics (examples)	Healthy life habits Clinical management of pathologies (symptom management, pathology adherence) Emotional and stress management Social management (job compatibility, social roles)	Healthy life habits Clinical management of pathologies (symptom management, pathology adherence) Emotional and stress management Social management (job compatibility, social roles)
Outcomes measured	Activation, anxiety and depression, disease burden, quality of life, resource use	Activation, anxiety and depression, disease burden, quality of life, resource use
Type of patients	Middle-aged people with multimorbidity	Middle-aged people with multimorbidity
Content development	Co-designed. A multidisciplinary group of professionals prepares and reviews the contents. New contents according to the dynamics of participation and the needs of the group that participates in the community	Co-designed. A multidisciplinary group of professionals prepares and reviews the contents.

Source: Based on TIDieR guide (https://doi.org/10.1136/bmj.g1687) and Taxonomy of self-management interventions for chronic conditions (16).

Table 2. Trial outcomes

VARIABLES	NAME	TYPE OF VARIABLE	MEASURES
Primary	PAM (Patient Activation Measure)	Ordinal qualitative	Likert scale: 0-100, where 100 indicates highest level of activation
Secondary	PHQ-9 (Patient Health Questionnaire)	Ordinal qualitative	Likert scale: Depression intervals: 0- 4, 5-9, 10-14, 15-19, 20-27
	HADS-A (Hospital Anxiety and Depression Scale: Subscale of Anxiety)	Ordinal qualitative	Likert scale: Scored each item 0-3. >8 indicates possible cases
	TBQ (Treatment Burden Questionnaire)	Ordinal qualitative	Likert scale: 0-20, where 20 indicates significant problem
	HRQoL (Health Related Quality of Life)	Ordinal qualitative	Likert scale: Never-very often
Sociodemographic	Age	Discrete quantitative	years
	Sex (Gender)	Categorical Qualitative	4 categories: 1-Male, 2- Female, 3- Other, 4- Refused to answer
	Nationality	Nominal	Open question
	Autonomous Community of residence	Categorical Qualitative	2 categories: 1-Madrid, 2-Canary Islands
	Marital status	Categorical Qualitative	5 categories: 1-Married/partner, 2- single, 3-separated, 4-divorced, 5- widowed
	Have children	Dichotomous qualitative	Yes/no
	Number of children	Discrete	Open question (number/units)
	Caring parents	Dichotomous qualitative	Yes/no

Figure 1.- Implementation strategies flow-chart



			Stud	y period		
		Preallo	ation	Postal	location	Close-out
	Phase 1	Enrolment	Baseline	6 months	12 months	18 months
Co-creation process	Х					
Eligibility creen	Х*	Х				
Informed consent	Х*	Х				
Interventions						
VCoP						
Usual Care						
Assessments						
Sociodemographic variables			Х			
Morbidity			Х			
Treatment			Х			
PAM			Х	Х	х	Х
PHQ-9			Х	Х	Х	Х
HADS-A			Х	Х	Х	Х
тво			Х	Х	Х	Х
E5-5D-5L			Х	Х	Х	Х
Use of resources				Х	Х	Х
Use of VCoP				Х	Х	
Unintended consequences				Х	Х	Х

Figure 2. Schedule of enrolment, interventions, and assessments

*The eligibility screen and informed consent of the co-creation phase are like the RCT phase.

HADS, Hospital Anxiety and Depression Scale; PAM, Patient Activation Measure; PHQ-9, Patient Health Questionnaire; TBQ, Treatment Burden Questionnaire; SPIRIT, Standard Protocol Items: Recommendations for Interventional Trials; VCoP, Virtual Community of Practice.

Figure 3. Project timeline

			2023	3							20	24										202	5						2026		
	8	9	10	11	12	1	2	3	4	5	6	7 8	9	10	11	12	1	2	3	4	5 6	;	8	ę	10	0	11	12	1	2 3	4
1 Phase 1: co-creation process																															
2 Phase 2: RCT																															
2.1. Recruitment period																															
2.2. Intervention application																															
2.3. Evaluations (baseline, 6, 12 and 18 months)																															
2.4. Results assessment																															
3 Phase 3: Cost-effectiveness analysis																															
4 Dissemination of results.																				T											
4. Dissemination of results.																															



Additional file 1 - SPIRIT-Outcomes 2022 Checklist (for combined completion of SPIRIT 2013 and SPIRIT-Outcomes 2022 items)

Section	Item	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
Administrative in	nformatio	n l		_
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	-	1
	2a	Trial identifier and registry name. If not yet registered, name of intended registry	-	4
Trial registration	2b	All items from the World HealthOrganization Trial RegistrationData Set	-	N/A
Protocol version	3	Date and version identifier	-	Left header
Funding	4	Sources and types of financial, material, and other support	-	4
	5a	Names, affiliations, and roles of protocol contributors	-	1-2
	5b	Name and contact information for the trial sponsor	-	2
Roles and responsibilitie s	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	-	N/A
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoringcommittee)		1-2
Introduction				
Background and rationale	ба	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	<u> </u>	5-6
	бb	Explanation for choice of comparators	-	5-6
Objectives	7	Specific objectives or hypotheses	-	6



Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	-	6
		Methods: Participants, interventions, and	outcomes	
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	-	7
Eligibility criteria	10	Inclusion and exclusion criteria forparticipants. If applicable, eligibility criteria for study centres and individuals who will perform. the interventions (eg, surgeons, psychotherapists)	-	7
	11a	Interventions for each group withsufficient detail to allow replication, including how and when they will be administered. (for specific guidance see TIDieR checklist and guide)	-	9 (See Table
Interventions	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	-	N/A
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	-	N/A
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	0, -	9 (See Table 1
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of theclinical relevance of chosen efficacy and harm outcomes is strongly recommended	<u> </u>	10-12 (See Table 2)



$\begin{array}{c}1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\9\\21\\22\\23\\24\\25\\27\\28\\29\\30\\31\\32\\33\\4\\5\\37\end{array}$	
36	
38 39	
40 41	
42 43	
44 45	
46 47	
48 49	
50	
52	
53 54	
55 56	
57 58	
59	
60	

Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
	12.1		Provide a rationale for the selection of the domain for the trial's primary outcome	10
	12.2		If the analysis metric for the primary outcome represents within- participant change, define, and justify the minimal important change in individuals	14
	12.3		If the outcome data collected are continuous but will be analyzed as categorical (method of aggregation), specify the cutoff values to be used	N/A
	12.4	0	If outcome assessments will be performed at several time points after randomization, state the time points that will be used for analysis	12 (See Figure 2)
	12.5	Rec	If a composite outcome is used, define all individual components of the composite outcome	N/A
Participa nt timeline	13	Time schedule of enrolment, interventions (including any run- ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	_	12 (See Figure 2)
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	2	14
	14.1		Define and justify the target difference between treatment groups.(eg, the minimal important difference)	14
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	1	8
Methods: Assign	ment of inte	erventions (for controlled trials)		
Allocation:				
Sequence generatio n	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enroll participants orassign interventions	_	13



Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	-	13
Implementation	16c	Who will generate the allocationsequence, who will enroll participants, and who will assignparticipants to interventions	-	8, 13
Blinding	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers,outcome assessors, data analysts), and how	-	13
(masking)	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	-	N/A
Methods: Data c	ollection, m	anagement, and analysis		
	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	-	10-12 (See Fi 2)
Data collection methods	18a.1		Describe what is known about the responsiveness of the study instruments in a population similar tothe study sample	
	18a.2		Describe who will assess the outcome (eg, nurse, parent)	13
		Plans to promote participant retention and complete follow-up, including list of any		



Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	-	18
Statistical methods	20a	Statistical methods for analyzing primary and secondary outcomes.Reference to where other details of the statistical analysis plan can be found, if not in the protocol	-	13
	20a.1		Describe any planned methods to account for multiplicity in the analysis or interpretation of the primary and secondary outcomes (eg, coprimary outcomes, same outcome assessed at multiple time points, or subgroup analyses of an outcome)	13
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	-	13
	20c	Definition of analysis population relating to protocol non- adherence (eg, as randomized analysis), and any statistical methods to handle missing data (eg, multiple imputation)	-	13
Methods: Monitor	ring			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed		12
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate thetrial	-	13
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	-	12



Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor		18
		Ethics and dissemination		
Research ethics approval	24	Plans for seeking research ethicscommittee/institutional review board (REC/IRB) approval	-	17
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	-	17
Consent or	26a	Who will obtain informed consent or assent from potential trial participants or authorized surrogates, and how (see Item 32)	-	17
assent	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	-	N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	-	18
Declaration of interests 28 Financial and other competing interests for principal investigators for the overall trial and each study site		-	18	
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such accessfor investigators	-	18
Ancillary and post-trial care 30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation Plane for investigators and sponsor to communicate		-	N/A	
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	<u> </u>	17
	31b	Authorship eligibility guidelines and any intended use of professional writers	-	N/A



Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	-	17
Appendices				
Informed consent materials	32	Model consent form and other related documentation given to participants and authorized surrogates	-	See Additional File 3
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	-	N/A

^aIt is strongly recommended that this checklist be read in conjunction with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) Statement paper for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license and is reproduced with permission. ^bIndicates page numbers and/or manuscript location: to be completed by authors.

Source: Butcher NJ, Monsour A, Mew EJ, et al. Guidelines for reporting outcomes in trial protocols: the SPIRIT-Outcomes 2022extension. JAMA. Published online December 13, 2022. doi:10.1001/jama.2022.21243

2	
3	Additional file 2 - Questionnaire on computer and internet use
4	
5 6	
7	QUESTIONNAIRE ON COMPUTER AND INTERNET USE
8	
9	(This questionnaire will be completed by the research team during the first telephone contact with the
10 11	patient).
12	
13	Patient ID:
14	Autonomous Community:
15	Referral health center/hospital:
16	
17 18	Please answer the following questions about computer and internet use:
19	I lease answer me jone millig questions about comparer and internet use.
20	1. What type of device do you own? (Check all that apply):
21	· Computer
22	- Tablet
23	- Laptop
24 25	- Smartphone
26	· smartphone
27	* To meet the study requirements, patients must have at least one device.
28	To meet the study requirements, patients must have at least one device.
29	2 De ven have Internet access on your devices?
30 31	 Do you have Internet access on your devices? Yes
32	
33	- No
34	
35	* To meet the study requirements, only patients that answer YES could participate.
36 37	
38	3. How often do you use the Internet (including email)?
39	· Never
40	· Less than once a month
41	· Once a month
42 43	• Once or twice a week
43 44	· Everyday
45	
46	* To meet the study requirements, patients who check ONE OF THE FIRST TWO BOXES will
47	not be able to participate.
48	
49 50	4. When you are online, which of the following activities do you do? (check all that apply):
51	· I check the email
52	· Web surfing / Searching information
53	Shopping / User accounts payment
54	· I play video games
55 56	· I download or listen to music
57	· I watch videos or movies
58	· I use social networks (e.g. Facebook, Instagram, Twitter, Snapchat, Telegram,)
59	· I send instant messages (e.g. Skype, WhatsApp, Facebook Messenger, Telegram)
60	· I read press news

- · I take courses or distance studies
- · Use of different Apps

* To meet the study requirements, patients must check AT LEAST 3 BOXES to participate.

tor peet terien only

Additional file 3 - Informed consent

Patient information sheet

Clinical trial

INTRODUCTION

Dear Sir or Madam,

We would like to inform you that we are implementing the clinical trial entitled "Effectiveness and cost-effectiveness of a virtual Community of Practice (CdPV web application) for improving the empowerment of middle-aged individuals with multimorbidity: RCT".

This is a multicenter project involving Madrid: PI22/01124, the project coordinator, and the Canary Islands: PI22/00691.

This study has been approved by the Ethics Committees for Clinical Research of the participating centers in accordance with current legislation, Organic Law 3/2018, of December 5, on the Protection of Personal Data and the Guarantee of Digital Rights, and the application of Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016. Here you will find the correct and sufficient information to evaluate and decide whether or not you want to participate in this study. To do so, please read this information sheet carefully, and we will clarify any doubts that may arise after the explanation. Furthermore, you may consult with anyone you deem appropriate.

Voluntary participation

You should be aware that your participation in this study is voluntary, and you have the right to choose not to participate or change your decision and withdraw your consent at any time. Your decision will not affect your relationship with your doctor, nor will it cause any harm to your treatment.

Who are the researchers?

BMJ Open

The research team is a multidisciplinary group of professionals, including medical doctors, psychologists, statisticians, healthcare service evaluators, general practitioners, nurses, and cardiologists. The team members are affiliated with the following institutions: Avedis Donabedian Foundation, Primary Care Management, and the Directorate General of Research, Teaching, and Innovation of the Ministry of Health of the Community of Madrid, as well as the Service for the Evaluation of the Canary Islands Health Service (SESCS).

STUDY DESCRIPTION

Why is this study being conducted?

The purpose of this study is to evaluate the effectiveness of a virtual Community of Practice (VCoP) for middle-aged individuals with multiple chronic diseases. We aim to improve their knowledge, skills, and self-confidence in managing their own health. This will be measured using the specific Patient Activation Measure (PAM) questionnaire, which assesses activation levels in individuals with chronic diseases, at 12-months, comparing it with the active control group.

Who can participate?

If you are between 30 and 60 years old, have been diagnosed with two or more chronic diseases, and have internet access at home and/or a smartphone, you are eligible to participate.

Study procedure:

There will be two study groups: the Intervention Group (GI) and the Control Group (GC). Participants will be randomly assigned to one of these groups. If you decide to participate in the study, you could be placed in either group.

If you choose to participate, what does your involvement entail?

Page 41 of 59

BMJ Open

The study will last for 18 months. At the beginning of the study and at 6, 12, and 18 months, participants will complete online questionnaires. These questionnaires will assess various aspects related to each participant's level of activation in health-related decisions (PAM questionnaire), depression using the self-administered Patient Health Questionnaire-9 (PHQ-9), anxiety using the self-administered Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A), treatment burden using the self-administered Treatment Burden Questionnaire (TBQ), and health-related quality of life using the self-administered E5-5D-5L questionnaire (EuroQol group). Completing these questionnaires will take approximately 30 minutes.

During the baseline visit, sociodemographic variables and other variables related to your chronic diseases and treatment will be collected. If necessary, access to your medical history may be granted to verify this information.

If you are randomly assigned to the IG, you will be offered the opportunity to participate for 18 months in a Virtual Community of Practice (VCoP) based on a web 2.0 platform. A registration link will be provided to you via email to initiate your voluntary participation.

In the Virtual Community of Practice (VCoP), you will have access to leisure and educational activities based on strategies that facilitate learning, as well as the exchange of knowledge and experiences among participants and a multidisciplinary team of professionals. Various topics related to health competencies, self-efficacy techniques, lifestyle, acceptance of chronic illness, and shared decision-making will be addressed. If you are randomly assigned to the CG, you will continue to receive the standard care and attention provided in regular clinical practice. Additionally, you will be offered the same educational content as the intervention group but self-administered.

Benefits and risk of participating in this study.

There are no anticipated physical or psychological risks associated with participating in this study. The main benefit for participants with multiple chronic diseases is the opportunity to improve their knowledge, skills, and self-confidence in managing their own health and healthcare.

Confidentiality

The processing, communication, and transfer of personal data of all participating individuals will comply with the provisions of Organic Law 3/2018, of December 5, on the Protection of Personal Data and Guarantee of Digital Rights, and the application of Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016, on the Protection of Personal Data (GDPR). It is important that you are aware of the following information:

In addition to the rights, you are already familiar with (access, modification, objection, and cancellation of data), you now also have the right to limit the processing of incorrect data, request a copy of the data you have provided for the study, or have them transferred to a third party (data portability). Similarly, you have the right to withdraw your consent for data processing; however, such withdrawal may result in your discontinuation of participation in the trial. To exercise your rights, please contact the principal investigator of the study. Please note that data cannot be deleted even if you discontinue participation in the trial or withdraw your consent for data processing, to ensure the validity of the research and comply with legal obligations and medication authorization requirements. You also have the right to file a complaint with the Data Protection Agency if you are not satisfied.

Altogether, the Center, the Sponsor, and the Investigator are each responsible for your data processing and are committed to comply with current data protection regulations. The data collected for the study will be identified using a code, so that no information

BMJ Open

that can identify you is included. Only your study doctor/collaborators will be able to link this data to you and your medical history. Therefore, your identity will not be disclosed to anyone else unless required by health authorities or in cases of medical emergency. The Research Ethics Committees, representatives of the Health Authority responsible for inspection, and authorized personnel from the Sponsor may access personal data to verify the study procedures and compliance with good clinical practice standards (always maintaining the confidentiality of the information).

The Investigator and the Sponsor are obligated to retain the data collected for the study for at least 25 years after its completion. Afterwards, your personal information will only be retained by the healthcare center for your health care purposes and by the Sponsor for other scientific research purposes if you have provided consent for such retention, and if allowed by law and applicable ethical requirements.

Additional information

As required by law, you will need to sign and date the informed consent document to participate.
Project coordinator. Principal investigator. (Madrid):

Ana Isabel González González.

Innovation and International Projects Unit.

Subdirección General de Investigación, Docencia e Innovación. Consejería de Sanidad

de la Comunidad de Madrid.

contact: aisabel.gonzalezg@salud.madrid.org

Principal investigator (CANARIAS):

Lilisbeth Perestelo Pérez, Servicio de Evaluación del Servicio Canario de la Salud

Contact: lperperr@gobiernodecanarias.org

tor beer terien ont

1 2 3 4 5	Informed consent for	patients
6 7 8 9 10 11	(name and surname) declares:	
12 13		
14 15	That I have read the Patient information sheet.	
16 17 18	That I could make any questions regarding the study	у
19 20	That I have enough information about the study	
21 22	I received this information from:	
23 24		
25		
26 27		
28		
29 30		
31	I understand that my participation is volunteer, and	I can withdraw it:
32 33 34	1. Whenever I want.	
35 36	2. I don't have to give any explanations.	
37 38	3. Without any repercussions for my healthcar	e.
39 40	- I freely give my consent to participate in the study	y and authorize the access and use of
41 42	my data under the conditions detailed in the information	ation sheet.
43 44	-	
45		
46 47	Name of the participant:	
48		
49 50	Date:	Signature:
51		
52 53		
54		
55 56	Invostigator name:	
57	Investigator name:	
58 50	Date:	Signature:
59 60		

to beet terien only

Additional file 4 - O'Halloran list

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
Α	A04	Weakness/Tiredness general	029	Chronic fatigue syndrome
			031	Myalgic encephalomyelitis
			030	Post viral fatigue syndrome
			028	Post viral syndrome
	A70	Tuberculosis	Τ	
	A79	Malignancy, NOS		
	A90	Congenital anomaly NOS/multiple		
В	B72	Hodgkin's disease/lymphoma		
	B73	Leukaemia		
	B74	Malignant neoplasm blood other	\mathbf{C}	
	B75	Benign/unspecified neoplasm blood	008	Myelodysplastic syndrome
			004	Polycythaemia rubra vera
	B78	Hereditary haemolytic anaemia	Τ	
	B81	Anaemia, Vit B12/folate deficiency		
	B82	Anaemia, other/unspecified		
	B83	Purpura/coagulation defects		
	B90	HIV infection/AIDS		
D	D72	Viral hepatitis	003	Hepatitis B
			008	Hepatitis C
			009	Hepatitis D
	D74	Malignant neoplasm stomach	Τ	
	D75	Malignant neoplasm colon/rectum		
	D76	Malignant neoplasm pancreas		

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
	D77	Malignant neoplasm digestive other/NOS		
	D81	Congenital anomaly digestive system	011	Atresia;biliary
			005	Cleft;palate/lip
			007	Disease;Hirschsprungs
			002	Harelip
			001	Megacolon;congenital
	D84	Congenital anomaly digestive system	Γ	
	D85	Duodenal ulcer		
	D86	Peptic ulcer other		
	D92	Diverticular disease		
	D93	Irritable bowel syndrome		
	D94	Chronic enteritis/ulcerative colitis	\mathbf{C}	
	D97	Liver disease NOS		
	D98	Cholecystitis/cholelithiasis		
	D99	Disease digestive system, other	029	Blind loop syndrome
			032	Insufficiency;pancreatic
			017	Insufficiency;vascul;mesentery
			013	Gluten sensitivity
			015	Intolerance;fat
			012	Intolerance;gluten
			054	Intolerance;lactose
			028	Malabsorption syndrome
			043	Pancreatitis
			036	Pyloric stenosis; acquired
			024	Sprue
			055	Stenosis; anal

 BMJ Open

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
			025	Stenosis; sigmoid colon
			016	Thrombosis;mesenteric
F	F74	Neoplasm of eye/adnexa	003	Carcinoma;eye
			002	Neoplasm malig;eye
	F83	Retinopathy		
	F84	Macular degeneration		
	F92	Cataract		
	F93	Glaucoma		
	F94	Blindness		
Н	H75	Neoplasm of ear	003	Carcinoma;ear
			002	Neoplasm malig;ear
	H82	Vertiginous syndrome		•
	H84	Presbyacusis		
	H86	Deafness		N 1.
K	K71	Rheumatic fever/heart disease	010	Carditis; rheumatic; chronic
			012	Myocarditis; rheumatic; chron
			015	Stenosis;arterial;rheumatic
			005	Stenosis;mitral;rheumatic
	K72	Neoplasm, cardiovascular	003	Carcinoma;cardiovascular
			002	Neoplasm malig;cardiovascu
	K73	Congenital anomaly, cardiovascular		
	K74	Ischaemic heart disease with angina		
	K75	Acute myocardial infarction		
	K76	Ischaemic heart disease without angina		
	K77	Heart failure		

CHAP	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
	K78	Atrial fibrillation/flutter		
	K79	Paroxysmal tachycardia		
	K80	Cardiac arrhythmia NOS		
	K81	Heart/arterial murmur NOS		
	K82	Pulmonary heart disease		
	K83	Heart valve disease NOS		
	K84	Heart disease, other		
	K86	Hypertension, uncomplicated		
	K87	Hypertension, complicated		
	K88	Hypertension, complicated Postural hypotension		
	K89	Transient cerebral ischaemia		
	K90	Stroke/cerebrovascular accident	\mathbf{N}	
	K91	Cerebrovascular disease		
	K92	Atherosclerosis/peripheral vascular disease		
	K93	Pulmonary embolism		
	K94	Phlebitis/thrombophlebitis		
	K95	Varicose veins of leg		
L	L71	Malignant neoplasm, musculoskeletal		
	L82	Congenital anomaly, musculoskeletal	001	Achondroplastic dwarf
			003	Clubfoot
			015	Curvature of spine; congenital
			025	Deformity;foot;congenital
			024	Dislocation; hip; congenital
			013	Ehlers Danlos syndrome
			021	Kyphoscoliosis; congenital

 BMJ Open

CHAP	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
			019	Kyphosis; congenital
			007	Lordosis;congenital
			018	Osteogenesis imperfecta
			027	Plagiocephaly
			012	Scoliosis;congenital
			014	Talipes
	L83	Neck syndrome		
	L84	Back syndrome without radiating pain		
	L85	Acquired deformity of spine		
	L86	Back syndrome with radiating pain		
	L88	Rheumatoid/seropositive arthritis		
	L89	Osteoarthritis of hip	\mathbf{N}	
	L90	Osteoarthritis of knee		
	L91	Osteoarthritis, other		
	L92	Shoulder syndrome		
	L93	Tennis elbow		
	L95	Osteoporosis		
	L99	Musculoskeletal disease, other	047	Arthropathy; Behcets syndrome
			087	Arthropathy;Reiters disease
			088	Chondromalacia;patella
			013	Disease; Pagets (bone)
			093	Dystrophy;muscular
			056	Lupus erythematosus
			025	Osteitis
			000	
			026	Osteitis deformans

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
			071	Progressive system sclerosis
			075	Reiters syndrome
			078	Repetitive Strain Injury
			069	Scleroderma;diffuse
			070	Scleroderma;localised
			028	Scleroderma;progressive
			033	Sjorgens syndrome
			065	Systemic lupus erythematosus
N	N73	Neurological infection, other		
	N74	Malignant neoplasm nervous system		
	N75	Benign neoplasm nervous system		
	N76	Neoplasm nervous system, unspecified	\mathbf{C}	
	N85	Congenital anomaly neurological		
	N86	Multiple sclerosis		
	N87	Parkinsonism		
	N88	Epilepsy		
	N89	Migraine		
	N90	Cluster headache		
	N92	Trigeminal neuralgia		
	N93	Carpal tunnel syndrome		
	N94	Peripheral neuritis/neuropathy		
	N99	Neurological disease, other	025	Arachnoiditis
			005	Atrophy;cerebral
			004	Chorea; Huntingtons
			027	Degeneration; cerebral
			010	Disease; motor neuron

BMJ Open

1	
2	
3	
4	
5	
6	
7	
8 9	
9 10	
11	
12	
12 13 14 15 16	
14	
15	
16	
17	
10	
18 19 20	
21	
-22	
23	
24	
25	
26 27	
27	
29	
30	
31	
32	
33	
34	
35	
36 37	
38	
39	
40	
41	
42	
43	
44	
45	
46	

CHAP	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
			042	Encephalopathy
			043	Encephalopathy;Wernickes
			011	Myasthenia Gravis
			003	Palsy;cerebral
			022	Palsy; infantile spastic
			040	Palsy; spastic
			017	Paralysis; infantile spastic
			018	Paraplegia
			020	Quadriplegia
			030	Syringomyelia
Р	P15	Chronic alcohol abuse		
	P70	Dementia	\mathbf{N}	
	P71	Organic psychosis, other		
	P72	Schizophrenia		
	P73	Affective psychosis		
	P74	Anxiety disorder/anxiety state		
	P75	Somatisation disorder		
	P76	Depressive disorder		
	P78	Neuraesthenia, surmenage		
	P79	Phobia/compulsive disorder		
	P80	Personality disorder	1	ien ony
	P81	Hyperkinetic disorder		
	P82	Post-traumatic stress disorder		
	P85	Mental retardation		
	P86	Anorexia nervosa/bulimia		
	P98	Psychosis NOS/other		

BMJ Open

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
	P99	Psychological disorders, other	005	Autism
			006	Autism;child
R	R84	Malignant neoplasm bronchus, lung		
	R85	Malignant neoplasm respiratory, other		
	R90	Hypertrophy tonsils/adenoids		
	R95	Chronic obstructive pulmonary disease		
	R96	Asthma		
	R99	Respiratory disease, other	015	Asbestosis
			018	Bronchiectasis
			004	Failure; respiratory
			009	Farmers lung
			019	Fibrosing alveolitis
			010	Fibrosis;pulmonary
			012	Pneumoconiosis
			020	Pneumonia; interstitial
S	S77	Malignant neoplasm of skin		0
	S86	Dermatitis, seborrhoeic		
	S 87	Dermatitis/atopic eczema		
	S91	Psoriasis		
	S96	Acne	007	Acne
			003	Acne; conglobulate (cystic)
			002	Acne;vulgaris
	S99	Skin disease, other	001	Acne;rosacea
			003	Dermatitis; herpetiformis
			034	Discoid lupus erythematosus
			042	Lichen sclerosus

 BMJ Open

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
			031	Necrobiosis lipoidica diabetic
			018	Pemphigus
			021	Rhinophyma
	T71	Malignant neoplasm thyroid		
	T73	Neoplasm endocrine other/uncertain	001	Carcinoma;endocrine
			002	Neoplasm malig;endocrine
	T80	Congenital anomaly endocrine/metabolic	007	Cretinism
			001	Disease;Hurlers
			002	Dwarfism
			005	Pseudohypoparathyroidism
	T81	Goitre		
	T82	Obesity	C1.	
	T83	Overweight		
	T85	Hyperthyroidism/thyrotoxicosis		
	T86	Hypothyroidism/myxoedema		
	T89	Diabetes, insulin dependent		
	Т90	Diabetes, non-insulin dependent		
	Т92	Gout		
	Т93	Lipid disorder		Acromegaly
	T99	Endocrine/metabolic/nutritional disease, other	001	Acromegaly
			006	Amyloidosis
			028	Cushings syndrome
			053	Cystic fibrosis
			011	Diabetes insipidus
			002	Disease;Addisons

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
			064	Disease;fibrocystic
			013	Disease;Gilberts
			018	Disease;Hashimotos
			046	Disease;Wilsons
			035	Haemochromatosis
			073	Homocystinuria
			036	Hyperaldosteronism
			037	Hyperparathyroidim
			069	Hyperprolactinaema
			030	Hypoparathyroidism
			023	Phenylketonuria
			043	Polycystic ovary syndrome
			026	Porphyria
			040	Stein Leventhal syndrome
			041	Thyroiditis
U	U75	Malignant neoplasm kidney		
	U76	Malignant neoplasm bladder		
	U77	Malignant neoplasm, urinary, other		
	U88	Glomerulonephritis/nephrosis		
	U99	Urinary disease, other	019	Diverticulitis;bladder
			023	Failure;renal;chronic
			022	Insufficiency; renal
			006	Necrosis; renal
			024	Necrosis; renal; papillary
			013	Reflux; ureteric
			028	Stenosis; artery; renal

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
			017	Stenosis; urethral
W	W15	Infertility/subfertility		
	W72	Malignant neoplasm related to fertility		
Х	X74	Pelvic inflammatory disease		
	X75	Malignant neoplasm cervix		
	X76	Malignant neoplasm breast female		
	X77	Malignant neoplasm genital female other		
	X99	Genital disease, other	016	Endometriosis
			009	Fistula;vaginal
Y	Y77	Malignant neoplasm prostate		
	Y78	Malignant neoplasm male genital, other		
	Y85	Benign prostatic hypertrophy		

N.B. Italics indicate that the ICPC-2 rubric is chronic only at the ICPC-2 PLUS level. Conditions listed in the 'ICPC-2 PLUS Code' column are those within the rubric which

have been labelled as chronic using the extended terminology of ICPC-2 PLUS.

Source: O'Halloran J, Miller GC, Britt H. Defining chronic conditions for primary care with ICPC-2. Family Practice [Internet]. 2004 Aug 1;21(4):381-6.

DICTAMEN DEL COMITÉ de ÉTICA DE LA INVESTIGACIÓN con MEDICAMENTOS

D. Roberto Collado Borrell, Secretario Técnico del COMITÉ de ÉTICA DE LA INVESTIGACIÓN con MEDICAMENTOS HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN

CERTIFICA

Que se ha evaluado la propuesta del promotor referida al estudio observacional:

Código PI22/01124

1 2

3

4

5 6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21 22

23

24

25

26 27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56 57 **TÍTULO:** "Efectividad y coste-efectividad de una Comunidad de Práctica virtual (CdPV aplicación web) para la mejora del empoderamiento de personas de mediana edad con multimorbilidad: ECA"

Protocolo versión 2. 29 de mayo de 2023. Hoja de Información al paciente y Consentimiento Informado Fase Ensayo Clínico versión 3. 7 de junio de 2023. Hoja de Información al paciente y Consentimiento Informado Fase Co-Diseño versión 1. 20 de marzo de 2023.

Promotor: Investigador

- El estudio se plantea siguiendo los requisitos legalmente establecidos, y su realización es pertinente.
- Se cumplen los requisitos necesarios de idoneidad del protocolo en relación con los objetivos del estudio y están justificados los riesgos y molestias previsibles para el sujeto.
- Es adecuado el procedimiento para obtener el consentimiento informado
- El alcance de las compensaciones económicas previstas no interfiere con el respeto a los postulados éticos.
- La capacidad del investigador y sus colaboradores, y las instalaciones y medios disponibles, tal y como ha sido informado, son apropiados para llevar a cabo el estudio.

Este CEIm actuando como comité evaluador, emite **dictamen favorable** y acepta que dicho estudio sea realizado en los centros siguientes por los investigadores principales que se relacionan a continuación:

Dra. Ana Isabel González González / Unidad de Innovación y Proyectos Internacionales - Consejería de Sanidad de la Comunidad de Madrid

Y HACE CONSTAR QUE:

1º En la reunión celebrada el día **05 de junio de 2023**, **acta 11/2023** se decidió emitir el informe correspondiente al estudio de referencia.

2º En dicha reunión se cumplieron los requisitos establecidos en la legislación vigente -Real Decreto 1090/2015 y Decreto 39/94 de la Comunidad de Madrid- para que la decisión del citado CEIm sea válida.

3º El CEIm, tanto en su composición, como en los PNT cumple con las normas de BPC (CPMP/ ICH/ 135/95)

4º La composición actual del CEIm es la siguiente:

D. ANDRÉS JESÚS MUÑOZ MARTÍN (Oncología Médica - Presidente) Dª. MARÍA LUISA NAVARRO GÓMEZ (Pediatría - Vicepresidenta) D. ROBERTO COLLADO BORRELL (Farmacia Hospitalaria - Secretario Técnico) D. JUAN ANTONIO ANDUEZA LILLO (Medicina Interna) D^a. BEATRIZ AUDIBERT AMOROTO (Licenciada en Derecho) D^a. MARÍA LUISA BAEZA OCHOA DE OCÁRIZ (Alergología) D^a. PILAR AITANA CALVO FERRÁNDIZ (Farmacología Clínica) D^a. ISABEL CASTREJÓN FERNÁNDEZ (Reumatología) D^a MARÍA DEL CARMEN DE LA CRUZ ARGUEDAS (Unidad de Apoyo a la Investigación) D. VICENTE DE LAS PEÑAS GIL (Psicología Clínica) D. JAVIER DE MIGUEL DÍEZ (Neumología) D^a. PATRICIA FONT LÓPEZ (Hematología y Hemoterapia) D^a. ISABEL GÓMEZ VALBUENA (Farmacia de Atención Primaria) D. PABLO GONZÁLEZ NAVARRO (Bioestad'sitica) D^a. MARÍA DEL CARMEN HERAS ESCOBAR (Enfermería) D^a. LUIS IBÁÑEZ SAMANIEGO (Digestivo) D^a. ANA MARÍA IGLESIAS MOHEDANO (Neurología) D. LUIS ANDRÉS LÓPEZ FERNÁNDEZ (Biología) D^a. ANA ESTHER LÓPEZ PÉREZ (Anestesiología v Reanimación) D. ANTONIO MUIÑO MIGUEZ (Medicina Interna) D^a. SARA PÉREZ RAMÍREZ (Oncología) D. JOSÉ LUIS REVUELTA HERRERO (Farmacia Hospitalaria) D. EDUARDO ZATARAÍN NICOLÁS (Cardiología) Lo que firmo en Madrid, a 07 de junio de 2023

Page 59 of 59





El estudio de investigación titulado: "Efectividad y coste-efectividad de una Comunidad de Práctica Virtual (CdPV aplicación web) para la mejora del empoderamiento de personas de mediana edad con multicomorbilidad: ECA", versión 1_19012023, con código CHUNSC_2023_06, del que es Investigador Principal la Dra. LILISBETH PERESTELO PEREZ, ha sido evaluado por el Comité de Ética de la Investigación con medicamentos del Complejo Hospitalario Universitario de Canarias (Provincia de Santa Cruz de Tenerife) en su sesión del 26/01/2023, y considera que:


Se cumplen los requisitos necesarios de idoneidad del Protocolo con los objetivos del estudio.

El procedimiento para obtener el consentimiento informado, incluyendo la hoja de información para los sujetos y el consentimiento informado, **versión 2, 13-03-2023** y la hoja de información al profesional y el consentimiento informado, **versión 2, 13-02-2023**, es adecuado.

La capacidad del Investigador y los medios disponibles son adecuados para llevar a cabo el estudio y no interfiere con el respeto a los postulados éticos.

Por todo ello, el Comité de Ética de la Investigación con medicamentos del Complejo Hospitalario Universitario de Canarias (Provincia de Santa Cruz de Tenerife) emite dictamen **FAVORABLE** para la realización de este estudio en el Servicio de Evaluación del Servicio Canario de la Salud (SESCS).

Secretario Técnico en funciones del CEIm Complejo Hospitalario Universitario de Canarias









INFORMACIÓN ADICIONAL:

BMJ Open

Es responsabilidad del investigador principal garantizar que todos los investigadores asociados con este proyecto conozcan las condiciones de aprobación y los documentos aprobados.

El Investigador Principal debe informar a la Secretaría del CEIm mediante una enmienda, informe anual de seguimiento o notificación, de:

• Cualquier cambio significativo en el proyecto y la razón de ese cambio, incluida una indicación de las implicaciones éticas (si las hubiera);

- Eventos adversos graves en los participantes y la acción tomada para abordar esos efectos;
- Cualquier otro evento imprevisto o inesperado, como desviaciones de protocolo;
 - El cambio de Investigador Principal;
 - · Informe anual de seguimiento;
 - La fecha de finalización del estudio;
 - Informe final del estudio y/o publicación de resultados.

Este documento ha sido firmado electrónicamente por: FERNANDO ALBERTO HIDALGO FIGUEROLA - FEA FARMACOLOGIA CLINICA

En la dirección https://sede.gobiernodecanarias.org/sede/verifica_doc?codigo_nde= puede ser comprobada la autenticidad de esta copia, mediante el número de documento electrónico siguiente: 0zDFQeTx3noGFkthCAAhjo43Y50CcLPRp FOr peer review only - http://br

El presente documento ha sido descargado el 15/02/2023 - 14:37:59



Fecha: 15/02/2023 - 14:02:24

BMJ Open

BMJ Open

Implementation of a virtual community of practice to promote the empowerment of middle-aged people with multimorbidity: Study protocol of a randomized controlled trial.

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-084937.R1
Article Type:	Protocol
Date Submitted by the Author:	28-Apr-2024
Complete List of Authors:	Campillejo, Alba; Community of Madrid Madrid Health Service, Foundation for Biosanitary Research and Innovation in Primary Care Gefaell-Larrondo, Ileana; Community of Madrid Madrid Health Service, Foundation for Biosanitary Research and Innovation in Primary Care Ramos-García, Vanesa; Canary Islands Health Service, Canary Islands Health Research Institute Foundation Koatz, Débora; Autonomous University of Barcelona, Avedis Donabedian Research Institute Foundation Santos-Álvarez, Anthea; Canary Islands Health Service, Canary Islands Health Research Institute Foundation Barrio-Cortes, Jaime; Community of Madrid Madrid Health Service, Foundation for Biosanitary Research and Innovation in Primary Care Gómez-Rueda, Sara; Community of Madrid Madrid Health Service, Gregorio Marañón Research Institute Calderón-Larrañaga, Amaia; Karolinska Institutet Cifuentes, Patricia; Community of Madrid Ministry of Health, University Hospital of Alcorcón Company-Sancho, Consuelo; Canary Islands Health Service, General Directorate of Ublic Health Domínguez-Coello, Santiago; Canary Islands Health Service, La Laguna Health Care Center - Family and Community Care teaching unit García-García, Francisco Javier; Canary Islands Health Service, Quality Care Unit - Nuestra Señora de La Candelaria University Hospital (HUNSC) Garrido-Elustondo, Sofía; Comunidad de Madrid Consejeria de Sanidad, Centre Family and Community Care Teaching Multiprofessional Unit González de León, Beatriz; Canary Islands Health Service, Tenerife Primary Care Management Ramón-Vazquez, José; Canary Islands Health Service, Tenerife Primary Care Management Martín, Candelaria; Hospital Universitario de Canarias, Internal Medicine Department Suárez-Fernández, Carmen; Community of Madrid Madrid Health Service, La Princesa Hospital Parra-Caballero, Pedro; Community of Madrid Madrid Health Service, La Princesa Hospital Vicente-Rabaneda, Esther F.; Community of Madrid Madrid Health Service, La Princesa Hospital

2 3	
4	
5	
6 7	
8	
9 10	
10 11	
12	
13 14	
15	
16	
17 18	
19	
20 21	
22	
23	
24 25	
26	
27 28	
29	
30	
31 32	
33	
34 35	
36	
36 37 38	
38 39	
40	
41 42	
43	
44 45	
45 46	
47	
48 49	
50	
51 52	
53	
54	
55 56	
57	
58 59	
60	

	Quiroga-Colina, Patricia; Community of Madrid Madrid Health Service, La Princesa Hospital Ramírez-Puerta, Ana; Community of Madrid Madrid Health Service, Technical Support Unit, Primary Care Management Ruíz-López, Marta; Community of Madrid Madrid Health Service, Vicente Muzas Health Center Tello-Bernabé, María-Eugenia; Community of Madrid Madrid Health Service, El Espinillo Health Center Sanchez-Gamborino, Estrella; Community of Madrid Madrid Health Service, Rafael Alberti Health Center Ugalde-Abiega, Beatriz; Community of Madrid Madrid Health Service, Ramón y Cajal University Hospital Vall-Roqué, Helena; Autonomous University of Barcelona, Avedis Donabedian Research Institute (FAD); Research Network on Chronicity Primary Care and Prevention and Health Promotion Duarte-Díaz, Andrea; Canary Islands Health Service, Canary Islands Health Research Institute Foundation Abt-Sacks, Analía; Canary Islands Health Service, Canary Islands Health Research Institute Foundation Hernández-Yumar, Aránzazu; Canary Islands Health Service, Canary Islands Health Research Institute Foundation Torres-Castaño, Alezandra; Canary Islands Health Service, Canary Islands Health Research Institute Foundation Alvarez-Pérez, Yolanda; Canary Islands Health Service, Canary Islands Health Research Institute Foundation Muth, Christiane; University Hospital OWL of Bielefeld University Campus Hospital Lippe, Department of General Practice and Family Medicine van den Akker, Marjan; University of Frankfurt, Institute of General Practice Montori, Victor; Mayo Clinic, Knowledge and Encounter Research Unit Orrego, Carola; Autonomous University of Barcelona, Avedis Donabedian Research Institute; Research Network on Chronicity Primary Care and Prevention and Health Promotion, Perestelo-Pérez, Lilisbeth; Canary Islands Health Service, Evaluation Unit, Research Network on Chronicity Primary Care and Prevention and Health Promotion, González-González, Ana Isabel ; Community of Madrid Madrid Health Service, Gregorio Marañón Research Institute; Community of
Primary Subject	General practice / Family practice
Heading:	General practice / Family practice
Secondary Subject Heading:	Health services research
Keywords:	Self-Management, Chronic Disease, Clinical Trial, Community-Based Participatory Research, GENERAL MEDICINE (see Internal Medicine)

SCHOLARONE[™] Manuscripts

2	
3	
4	
5	
6	
-	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
20	
21 22	
23	
24	
25	
26	
27	
28	
20	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	

TITLE PAGE

- TITLE Implementation of a virtual community of practice to promote the empowerment of middleaged people with multimorbidity: Study protocol of a randomized controlled trial.
- 7

1

2

3

4

5

6

1

AUTHORS AND AFFILIATIONS

Alba Campillejo-García^{1*}, Ileana Gefaell-Larrondo^{1,2*}, Vanesa Ramos-García^{2,3*}, Débora 8 Koatz^{2,4}*, Anthea Santos-Álvarez³, Jaime Barrio-Cortes^{1,2,5,6}, Sara Gómez-Rueda⁵, Amaia 9 Calderón⁷, Patricia Cifuentes⁸, M^a Consuelo Company-Sancho⁹, Santiago Domínguez-10 Coello¹⁰, Francisco Javier García-García¹¹, Sofía Garrido-Elustondo¹², Beatriz González de 11 12 León¹³, José Ramón-Vazquez¹³, M^a Candelaria Martín-González¹⁴, Carmen Suárez-13 Fernández¹⁵, Pedro Parra-Caballero¹⁵, Esther F. Vicente-Rabaneda¹⁵, Patricia Quiroga-Colina¹⁵, Ana Belén Ramírez-Puerta¹⁶, Marta Ruíz-López¹⁷, María Eugenia Tello-Bernabé^{2,18}, 14 Estrella Sánchez-Gamborino-Del-Río¹⁹, Beatriz Ugalde-Abiega²⁰, Helena Vall-Roqué^{2,4}, 15 Andrea Duarte-Díaz³, Analía Abt-Sacks³, Aránzazu Hernández-Yumar³, Alezandra Torres-16 Castaño³, Yolanda Álvarez-Pérez³, Christiane Muth²¹, Marjan van den Akker²², Victor M. 17 Montori²³, Carola Orrego^{2,4**}, Lilisbeth Perestelo-Pérez^{2,24} **, Ana Isabel González-18 González^{2,5,25 **} 19

- 21 ¹ Fundación para la Investigación e Innovación Biosanitaria en Atención Primaria, Madrid (FIIBAP), Spain
- 22 ² Red de Investigación de Cronicidad en Atención Primaria y Promoción para la Salud (RICAPPS), Spain
- 23 ³Canary Islands Health Research Institute Foundation, Tenerife, Spain
- 24 ⁴ Avedis Donabedian Research Institute (FAD), Universidad Autónoma de Barcelona, Spain
- 25 ⁵ Gregorio Marañón Research Institute (IiSGM), Madrid, Spain
- 26 ⁶ Universidad Camilo José Cela, Madrid, Spain
- 27 ⁷ Karolinska Institutet, Stockholm, Sweden 60

2 3	28	8 Their constant of Alberta Markeid Carrie
4 5 6		⁸ University Hospital of Alcorcón, Madrid, Spain
	29	⁹ Dirección General de Salud Pública, Santa Cruz de Tenerife, Spain
7 8	30	¹⁰ Centro de salud de La Victoria - Unidad docente de Atención Familiar y Comunitaria, Santa Cruz de Tenerife, Spain
9	31	¹¹ Hospital Universitario Nuestra Señora de La Candelaria (HUNSC)- Unidad de Calidad Asistencial, Santa Cruz de
10 11	32	Tenerife, Spain
12 13 14 15 16	33	¹² Unidad Docente Multiprofesional de Atención Familiar y Comunitaria Sureste. Unidad de Apoyo a la Investigación.
	34	Gerencia de Atención Primaria. Madrid, Spain
	35	¹³ Gerencia de Atención Primaria de Tenerife, Canary Islands, Spain
17 18	36	¹⁴ Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
19 20 21 22	37	¹⁵ Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain
	38	¹⁶ Technical Directorate of Project Integration and Control, Gerencia de Atención Primaria, Madrid, Spain
23 24	39	¹⁷ Centro de Salud Vicente Muzas, Madrid, Spain
25	40	¹⁸ Centro de Salud El Espinillo, Madrid, Spain
26 27	41	¹⁹ Centro de Salud Rafael Alberti, Madrid, Spain
28 29	42	²⁰ Hospital Universitario Ramón y Cajal, Madrid, Spain
30 31	43	²¹ Department of General Practice and Family Medicine, Medical School OWL, University Bielefeld, Bielefeld,
32 33	44	Germany.
34	45	²² Institute of General Practice, Goethe University, Frankfurt am Main, Germany.
35 36	46	²³ Knowledge and Evaluation Research Unit, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
37 38	47	²⁴ Evaluation Unit (SESCS). Canary Islands Health Service (SCS), Tenerife, Spain
 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 	48	²⁵ Innovation & International Projects Unit, Subdirección General de Investigación y Documentación, Viceconsejería
	49	de Sanidad de la Comunidad de Madrid, Spain
	50	de Saindae de la Comunicad de Madrid, Spain
	51	
	52	*Authors contributed equally
	53	** Senior authors contributed equally
	54	
	55	CORRESPONDING AUTHOR
	56	Ana Isabel González González. Address: C. de la Aduana, 29, Consejería de Sanidad, 28013
	57	Madrid. email: aisabel.gonzalezg@salud.madrid.org. Phone: +34 646107832.

58 ABSTRACT

59 Introduction

Empowering people living with multimorbidity (multiple chronic conditions) to gain greater confidence in managing their health can enhance their guality of life. Education focused on self-management is a key tool for fostering patient empowerment and is mostly provided on an individual basis. Virtual Communities of Practice (VCoP) present a unique opportunity for online education in chronic condition self-management within a social context. This research aims to evaluate the effectiveness/cost-effectiveness of individualized, online self-management education compared to VCoP among middle-aged individuals living with multiple chronic conditions.

68 Methods and analysis

People aged 30-60, living with >2 chronic conditions, and receiving care in primary care centers and outpatient hospital-based clinics in Madrid and Canary Islands will enroll in an 18month parallel-design, blinded (intervention assessment and data analysts), pragmatic (adhering to the intention-to-treat principle), individually randomized trial. The trial will compare two 12-month web-based educational offers of identical content; one delivered individually (control) and the other with online social interaction (VCoP, intervention). Using repeated measures mixed linear models, with the patient as random effect and allocation groups and time per group as fixed effects, we will estimate between-arm differences in the change in Patient Activation Measure (PAM) from baseline to 12 months (primary endpoint), including measurements at 6- and 18-months follow-up. Other outcomes will include measures of depression and anxiety, treatment burden, quality of life. In addition to a process evaluation of the VCoP, we will conduct an economic evaluation estimating the relative cost-effectiveness of the VCoP from the perspectives of both the National Health System and the Community.

82 Ethics and Dissemination

The trial was approved by Clinical Research Ethics Committees of Gregorio Marañón
University Hospital in Madrid/Nuestra Señora Candelaria University Hospital in Santa Cruz
de Tenerife. The results will be disseminated through workshops, policy briefs, peer-reviewed
publications, local/international conferences.

87 Trial registration: Clinical Trials.gov. NCT06046326

STRENGTHS AND LIMITATIONS OF THIS STUDY

Strengths

- Pragmatic, multicenter design enhances the generalizability of the findings.
- Comprehensive measures, including patient activation, mental health, and quality of life.
- Longitudinal follow-up over 18 months to assess interventions' sustained effects. •

Limitations

- Restricted to internet-accessible participants, impacting representativeness.
- Dependent on participants' engagement willingness in online communities. •

BMJ Open

97 INTRODUCTION

98 Multimorbidity is defined as the simultaneous presence of two or more chronic conditions in 99 the same individual (1). Multimorbidity is becoming increasingly prevalent globally (2). While 100 the prevalence of multimorbidity tends to rise with age (2), it is worth noting that more than 101 50% of individuals living with multiple chronic diseases are under the age of 65 (3–5).

Irrespective of age, individuals with multimorbidity tend to have a lower quality of life (6), use
more healthcare services (7), and die younger (8) than people living with no or one chronic
condition. However, how multimorbidity affects daily life may differ between middle-aged and
older people.

106 It is in middle age when most chronic diseases first manifest. For middle-aged individuals with 107 multimorbidity, the challenge lies in juggling the work of self-management with professional 108 careers, childcare, eldercare, and leisure (9). Healthcare research has not adequately addressed 109 the consequences of multimorbidity, in terms of an individual's capacity for self-care and the 110 significant disruptions to family life, leisure, and community and professional commitments 111 (10,11). Comprehensive, patient-centered strategies to address both medical and psychosocial 112 aspects of care are urgently needed for middle-aged adults living with multimorbidity (12).

Empowerment is the process by which individuals gain control over managing the conditions of their daily life. Empowered individuals take actions to enhance their quality of life and possess the necessary knowledge, skills, attitudes, and self-perception to adapt their behavior and collaborate with others when required to achieve optimal well-being (13). There is a need for effective interventions that promote empowerment, self-confidence, self-esteem, and the ability to cope with the profound implications of multiple chronic diseases.

BMJ Open

According to Wenger et al. (14), a Community of Practice (CoP) is a group of individuals engaged in a common activity who develop a shared identity, deepen their knowledge, and expand their experiences in a particular field through ongoing interactions that strengthen their relationships. A group of people sharing the common condition of multimorbidity may benefit from an intervention where they can interact, exchange knowledge, resources, information, and receive mutual and professional support.

Virtual Communities of Practice (VCoP) offer widespread access to information and opportunities for interaction among people facing similar situations, which is particularly valuable for individuals with chronic conditions. Unlike passive educational strategies, key benefits of VCoPs encompass receiving and providing information, offering social support, boosting patient optimism, improving coping skills, brightening mood, reducing anxiety, and managing stress more effectively (15,16). C. C.

METHODS AND ANALYSIS

Aim

The main objective of this study is to assess the effectiveness and cost-effectiveness of two online self-management programs for chronic diseases. The first is delivered through a VCoP, fostering a community-based approach (intervention), while the second is provided on an individual basis (control). Other secondary objectives will be taken into account.

Trial design

We will conduct an 18-month, pragmatic, multicenter, parallel, randomized controlled trial. See Additional file 1 for SPIRIT checklist.

BMJ Open

2		
3 4 5	141	Study setting
6 7	142	Both groups will receive the intervention online as an add-on to their usual care at primary care
8 9 10	143	practices and outpatient hospital-based clinics in Madrid and the Canary Islands, Spain.
11 12 13	144	Eligibility criteria and study population
14 15 16	145	Patients aged 30-60 and diagnosed with two or more chronic conditions will be identified by
17 18	146	their healthcare providers (primary care and hospital physicians and nurses) and proposed to
19 20 21	147	be screened by the research team for the following eligibility criteria:
22 23	148	Inclusion Criteria
24 25 26	149	1. Age 30 - 60 years.
27 28	150	2. Documentation of at least two chronic diseases in the electronic medical record (EMR)
29 30	151	at the time of inclusion.
31 32 33	152	3. Access to the internet at home or via a smartphone.
34 35	153	4. Ability to meet the study requirements [e.g., digital literacy questionnaire (Additional
36 37	154	file 2 shows this in more details)].
38 39 40	155	5. Signed, written, informed consent.
40 41 42	156	Exclusion Criteria
43 44	157	Exclusion Criteria 1. Institutionalized individuals.
45 46	158	2. Receiving Palliative care.
47 48 49	159	3. Telephone/email contact information missing from clinic databases.
50 51 52	160	Recruitment and Implementation Strategies for Health Care Providers in Madrid and
53 54 55	161	Canary Islands.
55 56 57 58 59 60	162	Recruitment Process

BMJ Open

Health care providers (HCPs) from Madrid and the Canary Islands will be invited to participate in recruiting subjects for the study. To facilitate this process, the research team will conduct informative sessions with HCPs, including nurses and physicians from outpatient clinics and primary care centers. These sessions will focus on detailing the project's objectives, outlining specific recruitment guidelines, and describing the responsibilities involved. Interested HCPs will then approach eligible patients, based on predefined inclusion criteria, to introduce them to the study's aims and requirements.

170 Patient Engagement and Information Dissemination

Patients expressing interest in the study will be contacted by a member of the researcher team. This step involves providing comprehensive information about the study, addressing any queries, and assessing the patients' familiarity with computer and internet usage. Following this, patients will gain access to a specialized web platform, designed exclusively for this project. This platform houses the informed consent document, which participants are required to understand and sign before proceeding. Subsequently, participants will complete baseline questionnaires, after which they will receive a one-year access to their assigned implementation strategy. For data management the patient ID will be anonymized. The study's flow-chart can be found in Figure 1.

180 Implementation Strategies Overview

181 To define the interventions, we used the taxonomy of self-management interventions for182 chronic diseases developed by Orrego et al. (17):

- 183 1) Intervention Group "e-mpoderaT" Platform:
- Platform Features: A gamified Virtual Community of Practice (VCoP), hosted on a
 Web 2.0 platform, will encourage the sharing of experiences and knowledge through

Page 11 of 59

1

BMJ Open

2		
3 4	186	collective learning (16). The platform will provide diverse educational and interactive
5 6	187	content, including forums, readings, resources, videos, games, and virtual sessions, all
7 8 9	188	aimed at enhancing self-care and promoting knowledge exchange.
9 10 11	189	• Customization and Support: Tailored to address the unique needs of people with
12 13	190	multimorbidity, this intervention will be co-created with patients and HCPs, leading to
14 15	191	the development of a "Patient Journey Map". A healthcare professional experienced in
16 17 18	192	facilitating patient groups will moderate the VCoP, ensuring active engagement,
19 20	193	addressing queries, and fostering communication with a multidisciplinary team of
21 22	194	experts, including general practitioners, cardiologists, psychologists, and nutritionists.
23 24 25	195	• Educational Focus: The content emphasizes patient empowerment dimensions like
25 26 27	196	health competence, behavioral change, symptom monitoring, and shared decision-
28 29	197	making, aligning with European guidelines for managing chronic diseases (16).
30 31	198	2) Control Group – Standard Care with Educational Access:
32 33 34	199	• Usual Care and Educational Resources: Participants in the control group will continue
35 36	200	receiving standard care in line with local guidelines. Additionally, they will have access
37 38	201	to a self-administered platform featuring the same educational content as the VCoP,
39 40 41	202	minus the interactive and engagement components.
42 43 44	203	Table 1 summarizes the implementation strategy.
45 46 47	204	Description of materials and outcome measures
48 49 50 51	205	Primary outcome
52 53	206	The primary outcome will be the level of patient activation, assessed using the Patient
54 55	207	Activation Measure (PAM) questionnaire (18,19). Higher levels of patient activation, as
56 57 58	208	measured by the PAM are linked to greater patient satisfaction, better quality of life, and
59 60	209	enhanced physical and mental functional status (18). This questionnaire consists of 13 items

BMJ Open

that evaluate knowledge, skills, and confidence for self-care in patients with chronic conditions.
Responses are measured on a Likert 1–4-point scale, resulting in a total score ranging from 0
to 100, with 100 indicating the highest level of patient activation. The Spanish-translated
version has been validated in patients with chronic diseases and exhibits good validity and
reliability properties (20). The e-mpoderaT research team has previously employed this
questionnaire in their studies (e-mpodera (21) and e-mpodera2 (22)).

216 Secondary outcomes

Depression: The Patient Health Questionnaire-9 (PHQ-9) (23) will be used to detect depression, characterize its severity (24), and support follow-up (25). Validated in Spanish (26), it consists of 9 items that assess the presence of depressive symptoms in the last 2 weeks. Each item has a severity index: 0 = "never", 1 = "some days", 2 = "more than half the days" and 3 = "almost every day". A score between 0-4 indicates no depressive symptoms, 5-9 mild depressive symptoms, 10-14 moderate depressive symptoms, 15-19 moderately-severe depressive symptoms, and 20-27 severe depressive symptoms.

Anxiety: The self-administered Hospital Anxiety and Depression Scale HADS-A subscale
 (27) is a 7-item questionnaire, validated in Spanish, and used in primary care (28–30). Items
 are scored from 0 to 3, with a score of 8 indicating possible and >10 probable anxiety with
 good specificity and predictive value (31).

Treatment burden: Based on the self-administered Treatment Burden Questionnaire - TBQ
 (32). A 10-item version was validated in primary care of the UK in patients with
 multimorbidity (33). It uses a Likert scale that ranges from 0 (not difficult / does not apply)
 to 4 (extremely difficult) to assess the burden related to taking medication, self-care,
 medical appointments, and the need for organization. We will translate and adapt the MTB
 Questionnaire using the forward and back-translation procedure.

BMJ Open

3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
20 21	
21	
22 23	
23 24	
24 25	
26 27	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

Health-related quality of life (HRQoL): We will assess this construct using the self-administered EQ-5D-5L (34) validated in Spanish and used in primary care (35). It enables
 the calculation of Quality-Adjusted Life Years (QALYs). The EQ-5D-5L descriptive
 system comprises five dimensions (mobility, personal care, daily activities,
 pain/discomfort, and anxiety/depression).

239 Explanatory and adjustment variables

Sociodemographic: Age (years), gender, nationality, whether they live in Madrid or
 Canarias, marital status (married/partner, single, separated, divorced, widowed), number of
 living children, whether they have caregiving duties for parents (yes/no), educational level
 (incomplete primary studies, complete primary studies, secondary education, university
 studies or equivalent), and current occupation (i.e., unemployed, employed, self-employed,
 sick leave, another situation).

Morbidity: Number and description of concomitant chronic diseases. This information will be collected by collaborating professionals coinciding with the baseline evaluation of each patient. An additional file of the O'Halloran list shows this in more detail (See Additional file 3) (36).

Treatment: We will record the quantity and details of medications prescribed for long-term
 (i.e., at least three months), continuous use for each patient. This information will be
 meticulously collected by our team of collaborating HCPs at the time of each patient's
 baseline assessment, ensuring accurate and comprehensive medication data.

Use of resources: Primary care (PC) visits, visits to the emergency department, visits to
 specialists, number of hospitalizations, lengths of stay.

Loss of productivity: Self-administered questionnaire about work absences related to the illness.

Use of VCoP: VCoP use data will be collected through the platform database.

Unintended consequences of the interventions will be monitored along the duration of the study (37).

All the outcome measures will be collected online from a patient self-reported questionnaire that the research team will elaborate. VCoP use data will be collected through the platform database database. See table 2 for more details.

Timeline

The primary outcome of our study (PAM), will be evaluated over a period of 12 months, starting from baseline. To ensure a thorough understanding of the PAM's progression, we will also conduct additional assessments at 6 and 18 months. Secondary outcome measures will be collected before the start of the VCoP intervention and at 6, 12 and 18 months. This information is shown with more details in Figure 2.

Data monitoring

The data will be monitored by the research team throughout the research process. Special attention will be paid to their quality and their correct collection. Primary analyzes will be conducted following completion of the 6-, 12-, and 18-month assessment questionnaires.

Randomization and blinding

The STATA 17.0 software will generate a random sequence used by an investigator to allocate participants to different platform groups and notify them via email, after they have been

BMJ Open

provided written consent. The intervention allocation will be blinded to participants, clinicians,and data analysts.

280 Statistical analysis

Sociodemographic and clinical baseline variables of both groups will be analyzed by descriptive methods according to the type of variable (mean [standard deviation (SD)], median [range], n [%]). The VCoP effect on the primary and secondary outcomes will be examined by means of repeated measures mixed linear models, with the intervention, time-point (0, 6, 12 and 18 months) and their interaction as fixed effects (along with other potential covariates), random intercepts for patients and clinicians, and unstructured covariance to account for within-subject correlations. We will also analyze the three-way interaction intervention \times time \times center, since usual care could vary between centers, leading to differential intervention effects. We expect to recruit enough clinicians to allow their inclusion in the model as a random intercept, but we will perform a sensitivity analysis as well as excluding this component. Between-group differences at each time-point will be compared by means of Wald's χ^2 test. We will perform the analyses on an intention-to-treat basis (a sensitivity analysis on the per-protocol population will also be performed). Multiple imputation will be used for missing data, if applicable (Markov Chain Monte Carlo multivariate imputation algorithm, with 10 imputations per variable). Analyses will be carried out with the statistical software R V.4.0.2 (http://www.R-project.org/).

We will conduct a cost-effectiveness analysis of the VCoP over 18 months, comparing it to standard care with educational access for middle-aged patients with multimorbidity. This analysis will include both direct healthcare costs and indirect costs like productivity losses. Costs for each patient will be calculated using healthcare resources and the indirect costs will

BMJ Open

be assessed based on productivity impacts. The study will also include the initial costs ofdeveloping and implementing the VCoP, and any costs incurred during the follow-up period.

The primary measure will be the cost per QALY gained. We will derive QALY estimates from the EQ-5D-5L questionnaire completed by patients at the study's start and each follow-up. The results will be presented as the incremental cost-effectiveness ratio (ICER), which compares cost and health outcomes differences between the VCoP and standard care. We will use robust statistical methods to ensure reliable ICER estimates and conduct sensitivity analyses to evaluate the effects of various factors on the results. The analysis will help determine whether the VCoP is a cost-effective option within our health system.

310 Sample size

To detect a mean difference of 4 points (SD = 10) in the PAM between the intervention and control groups, with individual randomization, 100 patients per group are required. This threshold of 4 points (SD = 10) was selected to capture clinically meaningful changes in patient activation (18). For this calculation, an alpha error of 0.05 and a power of 80% are assumed. This size is increased by the estimate of 20% loss, making a total of 240 patients.

¹ 316 **Patient and public involvement**

This protocol was developed without patient or public involvement. A group of middle-aged
patients with multimorbidity will actively participate in a content-design previous stage using
a co-creation methodology with virtual activities.

⁰ 320

 $\frac{1}{3}$ 321 ETHICS AND DISSEMINATION

Informed consent (Additional file 4) will be obtained from each participant before
 randomization. The project has been approved by the local Ethics Committees of each

324 participating Autonomous Community: Clinical Research Ethics Committee of Gregorio

Page 17 of 59

BMJ Open

Marañón University Hospital in Madrid (PI22/01124) and Nuestra Señora de Candelaria University Hospital in Santa Cruz de Tenerife (CHUNSC 2023 06) (Additional files 5 and 6). Patients will be personally informed by their physicians or nurses about the study and the possibility to participate during a programmed consultation. They will receive written information of the proposed research project, regarding its aims, the duration of their involvement, the expected benefits for them and the procedures involved in the participation. Recruiters will emphasize that enrollment in the study is voluntary, that participants can withdraw at any moment of the project, and that any decision they take in this respect will have no bearing on the medical care received. Once patients have signed the written informed consent, a researcher from the 'e-mpoderaT' team will contact them via phone and/or email to provide further information along with the necessary data (username and password) to login into the online platform. Additionally, recruiters will highlight that information generated by the study will be published, but no identification details will be divulged. Patients and healthcare professionals will be informed of whom to contact in case of any query, and research staff will be available to answer questions. We will prepare presentations to disseminate the study findings to healthcare stakeholders and patients, and at relevant national and international conferences. We aim to publish the results of the trial in peer-reviewed journals and try to grant public access to the full manuscripts. **TRIAL STATUS**

The recruitment of patients in each region will start in January-February 2024. The estimated
end date of the recruitment for this study is June 2024. This information is shown in more detail
in Figure 3.

/ 8 348

349 <u>REFERENCES</u>

1 2 3

4 5

6

7

18

- Van Den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: what's in a name? A review of literature. Eur J Gen Pract. enero de 1996;2(2):65-70.
- 8
 9 352 2. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of 10 353 multimorbidity and implications for health care, research, and medical education: a cross-11 354 sectional study. The Lancet. julio de 2012;380(9836):37-43.
- 355
 Wiolan C, Foguet-Boreu Q, Flores-Mateo G, Salisbury C, Blom J, Freitag M, et al. Prevalence, Determinants and Patterns of Multimorbidity in Primary Care: A Systematic Review of Observational Studies. Scuteri A, editor. PLoS ONE. 21 de julio de 2014;9(7):e102149.
- 359
 360
 361
 Prados-Torres A, Calderón-Larrañaga A, Hancco-Saavedra J, Poblador-Plou B, Van Den Akker M. Multimorbidity patterns: a systematic review. J Clin Epidemiol. marzo de 2014;67(3):254-66.
- 362
 363
 363
 363
 364
 5. Nicholson K, Terry AL, Fortin M, Williamson T, Bauer M, Thind A. Prevalence, characteristics, and patterns of patients with multimorbidity in primary care: a retrospective cohort analysis in Canada. Br J Gen Pract. septiembre de 2019;69(686):e647-56.
- 365
 366
 367
 368
 368
 368
 369
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
 368
- 33
 369
 370
 369
 370
 360
 371
 7. Hopman P, Heins MJ, Rijken M, Schellevis FG. Health care utilization of patients with multiple chronic diseases in The Netherlands: Differences and underlying factors. Eur J Intern Med. abril de 2015;26(3):190-6.
- 372 8. Willadsen T, Siersma V, Nicolaisdóttir D, Køster-Rasmussen R, Jarbøl D, Reventlow S,
 373 et al. Multimorbidity and mortality: A 15-year longitudinal registry-based nationwide
 374 Danish population study. J Comorbidity. 1 de enero de 2018;8(1):2235042X1880406.
- 42
 43
 43
 44
 376
 9. Ko D, Bratzke LC, Roberts T. Self-management assessment in multiple chronic conditions: A narrative review of literature. Int J Nurs Stud. julio de 2018;83:83-90.
- 45
 46
 47
 378
 48
 379
 49
 10. Lachman ME, Teshale S, Agrigoroaei S. Midlife as a pivotal period in the life course: Balancing growth and decline at the crossroads of youth and old age. Int J Behav Dev. enero de 2015;39(1):20-31.
- 380
 51
 52
 53
 381
 52
 53
 382
 11. Leppin A, Montori V, Gionfriddo M. Minimally Disruptive Medicine: A Pragmatically Comprehensive Model for Delivering Care to Patients with Multiple Chronic Conditions. Healthcare. 29 de enero de 2015;3(1):50-63.
- 383
 383
 384
 56
 384
 57
 385
 386
 386
 387
 12. Dinh TS, Brünn R, Schwarz C, Brueckle MS, Dieckelmann M, González González AI, et al. How do middle-aged patients and their healthcare providers manage multimorbidity? Results of a qualitative study. Prazeres F, editor. PLOS ONE. 31 de agosto de 2023;18(8):e0291065.
- 60

2 3 4 5	387 388	13.	EMPATHiE Consortium. Final summary report: EMPATHiE, empowering patients in the management of chronic diseases. 2014.
6 7 8	389 390	14.	Wenger E. Communities of Practice and Social Learning Systems. Organization. mayo de 2000;7(2):225-46.
9 10 11 12	391 392	15.	Rodgers S, Chen Q. Internet Community Group Participation: Psychosocial Benefits for Women with Breast Cancer. J Comput-Mediat Commun. julio de 2005;10(4):00-00.
13 14 15 16 17	393 394 395 396	16.	Koatz D, Torres-Castaño A, Salrach-Arnau C, Perestelo-Pérez L, Ramos-García V, González-González AI, et al. Exploring value creation in a virtual community of practice: a framework analysis for knowledge and skills development among primary care professionals. BMC Med Educ. 7 de febrero de 2024;24(1):121.
18 19 20 21 22 23	397 398 399 400	17.	Orrego C, Ballester M, Heymans M, Camus E, Groene O, Niño De Guzman E, et al. Talking the same language on patient empowerment: Development and content validation of a taxonomy of self-management interventions for chronic conditions. Health Expect. octubre de 2021;24(5):1626-38.
24 25 26 27	401 402 403	18.	Mosen DM, Schmittdiel J, Hibbard J, Sobel D, Remmers C, Bellows J. Is Patient Activation Associated With Outcomes of Care for Adults With Chronic Conditions?: J Ambulatory Care Manage. enero de 2007;30(1):21-9.
28 29 30 31 32	404 405 406	19.	Hibbard JH, Greene J, Overton V. Patients With Lower Activation Associated With Higher Costs; Delivery Systems Should Know Their Patients' 'Scores'. Health Aff (Millwood). febrero de 2013;32(2):216-22.
33 34 35 36 37	407 408 409 410	20.	Moreno-Chico C, González-de Paz L, Monforte-Royo C, Arrighi E, Navarro-Rubio MD, Gallart Fernández-Puebla A. Adaptation to European Spanish and psychometric properties of the Patient Activation Measure 13 in patients with chronic diseases. Fam Pract. octubre de 2017;34(5):627-34.
38 39 40 41 42 43	411 412 413 414	21.	Orrego C, Perestelo-Pérez L, González-González AI, Ballester-Santiago M, Koatz D, Pacheco-Huergo V, et al. A Virtual Community of Practice to Improve Primary Health Care Professionals' Attitudes Toward Patient Empowerment (e-MPODERA): A Cluster Randomized Trial. Ann Fam Med. mayo de 2022;20(3):204-10.
44 45 46 47	415 416 417	22.	Koatz D, Torres Castaño A, Ramos García V, Vall Roqué H, Toledo Chávarri A, Cifuentes Pérez P, et al. A Virtual Community of Practice (VCoP) for people with ischemic heart disease: the implementation process. Int J Integr Care. 4 de noviembre de 2022;22(S3):404.
48 49 50 51	418 419	23.	Spitzer RL. Validation and Utility of a Self-report Version of PRIME-MDThe PHQ Primary Care Study. JAMA. 10 de noviembre de 1999;282(18):1737.
52 53 54	420 421	24.	Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med. septiembre de 2001;16(9):606-13.
55 56 57 58 59 60	422 423 424	25.	Löwe B, Kroenke K, Herzog W, Gräfe K. Measuring depression outcome with a brief self- report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). J Affect Disord. julio de 2004;81(1):61-6.

- 425
 426 26. Diez-Quevedo C, Rangil T, Sanchez-Planell L, Kroenke K, Spitzer RL. Validation and 426 Utility of the Patient Health Questionnaire in Diagnosing Mental Disorders in 1003 General 427 Hospital Spanish Inpatients: Psychosom Med. julio de 2001;63(4):679-86.
- 428
 428
 429
 429
 429
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
- 431
 431
 432
 432
 433
 434
 435
 435
 435
 436
 437
 437
 438
 439
 439
 430
 430
 431
 432
 433
 433
 433
 434
 435
 435
 436
 437
 437
 438
 438
 439
 439
 430
 430
 430
 431
 431
 432
 433
 433
 434
 435
 435
 436
 437
 437
 438
 438
 439
 439
 430
 430
 430
 431
 431
 432
 433
 433
 434
 435
 435
 436
 437
 437
 438
 438
 439
 439
 439
 430
 430
 431
 431
 432
 433
 433
 433
 434
 435
 435
 436
 437
 438
 439
 439
 439
 439
 430
 430
 431
 432
 433
 433
 433
 434
 434
 435
 435
 436
 437
 438
 438
 439
 439
 439
 439
 430
 431
 431
 432
 433
 433
 434
 434
 435
 435
 436
 436
 437
 438
- 434
 435
 436
 436
 437
 438
 438
 439
 439
 436
 436
 436
 436
 437
 436
 437
 438
 439
 439
 439
 430
 430
 430
 431
 431
 432
 432
 433
 434
 435
 435
 435
 436
 437
 437
 438
 439
 439
 439
 439
 439
 430
 430
 430
 431
 431
 432
 432
 433
 434
 435
 435
 435
 436
 437
 437
 438
 438
 439
 439
 439
 439
 430
 430
 430
 431
 431
 431
 432
 432
 433
 434
 435
 435
 435
 436
 436
 437
 437
 438
 438
 438
 439
 439
 439
 439
 430
 430
 430
 431
 431
 431
 432
 434
 435
 434
 435
 434
 435
 435
 435
 436
 436
 436
 436
 436
 436
 437
 437
 438
 438
 438
 438
 438
 438
 438
 438
 438
 438
 438
 438
 438
 438
 438
 439
 439
 439
 439
 439
 439
 430
 430
 431
 431
 431
 432
 432
 434
 435
 434
 435
 435
 436
 436
 437
 438
 438
 438
 438
 438
 438
 438
 439
 439
 438
 438
 438
- 437
 437
 438
 438
 439
 30. Moryś JM, Bellwon J, Adamczyk K, Gruchała M. Depression and anxiety in patients with coronary artery disease, measured by means of self-report measures and clinician-rated instrument. Kardiol Pol. 25 de enero de 2016;74(1):53-60.
- 440
 441
 441
 441
 442
 442
 442
 443
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
 444
- 443
 32. Tran VT, Harrington M, Montori VM, Barnes C, Wicks P, Ravaud P. Adaptation and validation of the Treatment Burden Questionnaire (TBQ) in English using an internet platform. BMC Med. diciembre de 2014;12(1):109.
- 446
 446
 447
 448
 448
 448
 446
 447
 448
 447
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
 448
- 449
 450
 450
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
 451
- 43
 44
 453
 454
 453
 454
 35. Herdman M, Badia X, Berra S. El EuroQol-5D: una alternativa sencilla para la medición de la calidad de vida relacionada con la salud en atención primaria. Aten Primaria. 2001;28(6):425-9.
- 47
 48
 455
 456
 36. O'Halloran J, Miller GC, Britt H. Defining chronic conditions for primary care with ICPC2. Fam Pract. 1 de agosto de 2004;21(4):381-6.
- 457
 458
 458
 458
 459
 37. Ziebland S, Hyde E, Powell J. Power, paradox and pessimism: On the unintended consequences of digital health technologies in primary care. Soc Sci Med. noviembre de 2021;289:114419.
- 55 56

50

1 2 3

4

5

6

29

- 57 58
- 59 60

DECLARATIONS

VR, DK, JB, SGE, HVR, ADD, CM, MvdA, CO, LPP and AIGG contributed to the design of the study. AIGG and LPP are the guarantors. ACG and IGL wrote the first draft of the manuscript. VR, DK, ASA, JB, SGR, AC, PC, CCS, SDC, JGG, SGE, BGL, JV, CMG, CSF, PPC, EVR, PQC, ARP, MRL, ETB, ESG, BUA, HVR, ADD, AAS, AHY, ATC, YAP, CM, MvdA, VM, CO, LPP and AIGG contributed to the manuscript. The corresponding author attests that all listed authors meet the authorship criteria and that no others meeting the criteria have been omitted.

Funding

This work was supported by Instituto de Salud Carlos III (ISCIII), grant number PI22/01124 and PI22/00691 and co-funded by the European Union. Funding has been provided as well from the RICORS, code RD21/0016/00028 (Redes de Investigación Cooperativa Orientadas a Resultados en Salud) networks. The funders have no role in the study design.

Consent for publication

All authors read, approved the final manuscript and .gave their consent for publication.

Availability of data and materials

To maintain participants confidentiality, all information will be stored with anonymized identification code (ID code) numbers. All data will be stored on an electronic database management system located on a secure server with password-controlled access provided for research data collection. The Research Ethics Committees, the representatives of the Health Authority in matters of inspection and the personnel authorized by the Promoter, may only

1 2		
3 4	483	access to check personal data, clinical study procedures and compliance with the rules of good
5 6	484	clinical practice (always maintaining the confidentiality of information). Data will be available
7 8 9	485	for any audit process.
10 11 12	486	Competing interests
13 14 15	487	The authors declare no conflict of interest.
16 17 18 19	488	Acknowledgements
20 21 22	489	Avedis Donabedian Research Institute has been actively engaged in this area of research right
22 23 24	490	from the beginning. We sincerely appreciate their immense efforts and support, as this research
25 26 27	491	would not be possible without their valuable contributions.
28 29	492	Word count
30 31 32	493	2724
33 34 35	494	2724 Figure legend
36 37	495	Figure 1. Implementation strategies flow-chart
38 39 40	496	Figure 2. Schedule of enrolment, interventions, and assessments
41 42	497	Figure 3. Project timeline
43 44		
45 46		
47 48		
49		
50 51		
51 52		
53		
54 55		
55 56		
57		
58 59		
60		

Table 1. Implementation strategy.

INTERVENTION	INTERVENTION GROUP	ACTIVE CONTROL
COMPONENTS	"Virtual Community of Practice"	"Self-administered education"
	Provision of information	
	Skills training	
	Emotional support	
	Proposal of objectives and action plans	
Provisioning and	Training in self-monitoring of	Provision of information
support methods	symptoms and monitoring of healthy	Using reminders
	behaviors	
	Using reminders	
	Social support by peers and	
	professionals (key to the intervention)	
Type of encounters	Support sessions	Self-administered intervention
Support modality	Remote (web-based)	Remote (web-based)
T	Web platform compatible with mobile	Web platform compatible with mobile
Type of platform	devices	devices
Τ	Synchronous (webinar-type activities,	
Type of	virtual meetings) and asynchronous	Asynchronous (web)
communication	(web)	• • • • •
Recipients	In a group	Individual
Type of providers	Professionals in primary and	
interacting with	specialized care medicine, nursing,	There is no interaction with patients.
patients	psychology.	
Setting	Primary care patients	Primary care patients
	Healthy life habits	Healthy life habits
	Clinical management of pathologies	Clinical management of pathologies
	(symptom management, pathology	(symptom management, pathology
Content topics	adherence)	adherence)
(examples)	Emotional and stress management	Emotional and stress management
	Social management (job compatibility,	Social management (job compatibility
	social roles)	social roles)
0.4	Activation, anxiety and depression,	Activation, anxiety and depression,
Outcomes	disease burden, quality of life,	disease burden, quality of life, resource
measured	resource use	use
True of a time	Middle-aged people with	Middle-aged people with
Type of patients	multimorbidity	multimorbidity
	Co-designed. A multidisciplinary	
	group of professionals prepares and	
Content	reviews the contents. New contents	Co-designed. A multidisciplinary
Content	according to the dynamics of	group of professionals prepares and
development	participation and the needs of the	reviews the contents.
	group that participates in the	
	community	

Source: Based on TIDieR guide (https://doi.org/10.1136/bmj.g1687) and Taxonomy of self-management interventions for chronic conditions (16).


For beer teries only

Table 2. Trial outcomes

VARIABLES	NAME	TYPE OF VARIABLE	MEASURES
Primary	PAM (Patient Activation Measure)	Ordinal qualitative	Likert scale: 0-100, where 100 indicates highest level of activation
Secondary	PHQ-9 (Patient Health Questionnaire)	Ordinal qualitative	Likert scale: Depression intervals: 0- 4, 5-9, 10-14, 15-19, 20-27
	HADS-A (Hospital Anxiety and Depression Scale: Subscale of Anxiety)	Ordinal qualitative	Likert scale: Scored each item 0-3. >8 indicates possible cases
	TBQ (Treatment Burden Questionnaire)	Ordinal qualitative	Likert scale: 0-20, where 20 indicates significant problem
	HRQoL (Health Related Quality of Life)	Ordinal qualitative	Likert scale: Never-very often
Sociodemographic	Age	Discrete quantitative	years
	Sex (Gender)	Categorical Qualitative	4 categories: 1-Male, 2- Female, 3- Other, 4- Refused to answer
	Nationality	Nominal	Open question
	Autonomous Community of residence	Categorical Qualitative	2 categories: 1-Madrid, 2-Canary Islands
	Marital status	Categorical Qualitative	5 categories: 1-Married/partner, 2- single, 3-separated, 4-divorced, 5- widowed
	Have children	Dichotomous qualitative	Yes/no
	Number of children	Discrete	Open question (number/units)
	Caring parents	Dichotomous qualitative	Yes/no

VARIABLES	NAME	TYPE OF VARIABLE	MEASURES
	Educational level	Categorical Qualitative	4 categories: 1-Incomplete primary studies, 2-complete primary studies, 3-secondary education, 4-university studies or equivalent
	Current occupation	Nominal	Open question
Multimorbidity	Number and description of concomitant chronic diseases	Discrete / Nominal	O'Halloran list
Treatment	Number and description of chronic treatments	Discrete / Nominal	Open question (number of treatments in electronic medical record)

Figure 1.- Implementation strategies flow-chart



		Preallo	ation	Postal	Close-out	
	Phase 1	Enrolment	Baseline	6 months	12 months	18 months
Co-creation process	Х					
Eligibility creen	Х*	Х				
Informed consent	Х*	Х				
Interventions						
VCoP						
Usual Care						
Assessments						
Sociodemographic variables			Х			
Morbidity			Х			
Treatment			Х			
PAM			Х	Х	х	Х
PHQ-9			Х	Х	Х	Х
HADS-A			Х	Х	Х	Х
тво			Х	Х	Х	Х
E5-5D-5L			Х	Х	Х	Х
Use of resources				Х	Х	Х
Use of VCoP				Х	Х	
Unintended consequences				Х	Х	Х

Figure 2. Schedule of enrolment, interventions, and assessments

*The eligibility screen and informed consent of the co-creation phase are like the RCT phase.

HADS, Hospital Anxiety and Depression Scale; PAM, Patient Activation Measure; PHQ-9, Patient Health Questionnaire; TBQ, Treatment Burden Questionnaire; SPIRIT, Standard Protocol Items: Recommendations for Interventional Trials; VCoP, Virtual Community of Practice.

Figure 3. Project timeline

			2023	3							20	24										202	5							20	26
	8	9	10	11	12	1	2	3	4	5	6	7 8	9	10	11	12	1	2	3	4	5 6	;	8	ę	10	0	11	12	1	2 3	4
1 Phase 1: co-creation process																															
2 Phase 2: RCT																															
2.1. Recruitment period																															
2.2. Intervention application																															
2.3. Evaluations (baseline, 6, 12 and 18 months)																															
2.4. Results assessment																															
3 Phase 3: Cost-effectiveness analysis																															
4 Dissemination of results.																				T											
4. Dissemination of results.																															



Additional file 1 - SPIRIT-Outcomes 2022 Checklist (for combined completion of SPIRIT 2013 and SPIRIT-Outcomes 2022 items)

Section	Item	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
Administrative in	nformatio	n l		_
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	-	1
	2a	Trial identifier and registry name. If not yet registered, name of intended registry	-	4
Trial registration	2b	All items from the World HealthOrganization Trial RegistrationData Set	-	N/A
Protocol version	3	Date and version identifier	-	Left header
Funding	4	Sources and types of financial, material, and other support	-	4
	5a	Names, affiliations, and roles of protocol contributors	-	1-2
	5b	Name and contact information for the trial sponsor	-	2
Roles and responsibilitie s	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	-	N/A
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoringcommittee)		1-2
Introduction				
Background and rationale	ба	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	<u> </u>	5-6
	бb	Explanation for choice of comparators	-	5-6
Objectives	7	Specific objectives or hypotheses	-	6



Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	-	6
		Methods: Participants, interventions, and	outcomes	
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	-	7
Eligibility criteria	10	Inclusion and exclusion criteria forparticipants. If applicable, eligibility criteria for study centres and individuals who will perform. the interventions (eg, surgeons, psychotherapists)	-	7
	11a	Interventions for each group withsufficient detail to allow replication, including how and when they will be administered. (for specific guidance see TIDieR checklist and guide)	-	9 (See Table
Interventions	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	-	N/A
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	-	N/A
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	0, -	9 (See Table 1
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of theclinical relevance of chosen efficacy and harm outcomes is strongly recommended	<u> </u>	10-12 (See Table 2)



$\begin{array}{c}1\\2\\3\\4\\5\\6\\7\\8\\9\\10\\11\\12\\13\\14\\15\\16\\17\\18\\9\\21\\22\\23\\24\\25\\27\\28\\9\\30\\31\\32\\33\\4\\5\\37\end{array}$	
36	
38 39	
40 41	
42 43	
44 45	
46 47	
48 49	
50	
52	
53 54	
55 56	
57 58	
59	
60	

Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
	12.1		Provide a rationale for the selection of the domain for the trial's primary outcome	10
	12.2		If the analysis metric for the primary outcome represents within- participant change, define, and justify the minimal important change in individuals	14
	12.3		If the outcome data collected are continuous but will be analyzed as categorical (method of aggregation), specify the cutoff values to be used	N/A
	12.4	0	If outcome assessments will be performed at several time points after randomization, state the time points that will be used for analysis	12 (See Figure 2)
	12.5	Rec	If a composite outcome is used, define all individual components of the composite outcome	N/A
Participa nt timeline	13	Time schedule of enrolment, interventions (including any run- ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	_	12 (See Figure 2)
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	2	14
	14.1		Define and justify the target difference between treatment groups.(eg, the minimal important difference)	14
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	1	8
Methods: Assign	ment of inte	erventions (for controlled trials)		
Allocation:				
Sequence generatio n	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enroll participants orassign interventions	_	13



Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	-	13
Implementation	16c	Who will generate the allocationsequence, who will enroll participants, and who will assignparticipants to interventions	-	8, 13
Blinding	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers,outcome assessors, data analysts), and how	-	13
(masking)	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	-	N/A
Methods: Data c	ollection, m	anagement, and analysis		
	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	-	10-12 (See Fi 2)
Data collection methods	18a.1		Describe what is known about the responsiveness of the study instruments in a population similar tothe study sample	
	18a.2		Describe who will assess the outcome (eg, nurse, parent)	13
		Plans to promote participant retention and complete follow-up, including list of any		



Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	-	18
	20a	Statistical methods for analyzing primary and secondary outcomes.Reference to where other details of the statistical analysis plan can be found, if not in the protocol	-	13
Statistical methods	20a.1		Describe any planned methods to account for multiplicity in the analysis or interpretation of the primary and secondary outcomes (eg, coprimary outcomes, same outcome assessed at multiple time points, or subgroup analyses of an outcome)	13
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	-	13
	20c	Definition of analysis population relating to protocol non- adherence (eg, as randomized analysis), and any statistical methods to handle missing data (eg, multiple imputation)	-	13
Methods: Monitor	ring			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed		12
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate thetrial	-	13
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	-	12



Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor		18
		Ethics and dissemination		
Research ethics approval	24	Plans for seeking research ethicscommittee/institutional review board (REC/IRB) approval	-	17
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	-	17
Consent or	26a	Who will obtain informed consent or assent from potential trial participants or authorized surrogates, and how (see Item 32)	-	17
assent	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	-	N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	-	18
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	-	18
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such accessfor investigators	-	18
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	-	N/A
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	<u> </u>	17
	31b	Authorship eligibility guidelines and any intended use of professional writers	-	N/A



Section	Item No.	SPIRIT 2013 Item	SPIRIT-Outcomes 2022 item	Location Reported
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	-	17
Appendices				
Informed consent materials	32	Model consent form and other related documentation given to participants and authorized surrogates	-	See Additional File 3
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	-	N/A

^aIt is strongly recommended that this checklist be read in conjunction with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) Statement paper for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license and is reproduced with permission. ^bIndicates page numbers and/or manuscript location: to be completed by authors.

Source: Butcher NJ, Monsour A, Mew EJ, et al. Guidelines for reporting outcomes in trial protocols: the SPIRIT-Outcomes 2022extension. JAMA. Published online December 13, 2022. doi:10.1001/jama.2022.21243

2	
3	Additional file 2 - Questionnaire on computer and internet use
4	
5 6	
7	QUESTIONNAIRE ON COMPUTER AND INTERNET USE
8	
9	(This questionnaire will be completed by the research team during the first telephone contact with the
10 11	patient).
12	
13	Patient ID:
14	Autonomous Community:
15	Referral health center/hospital:
16	
17 18	Please answer the following questions about computer and internet use:
19	I lease answer me jone millig questions about comparer and internet use.
20	1. What type of device do you own? (Check all that apply):
21	· Computer
22	- Tablet
23	- Laptop
24 25	- Smartphone
26	· smartphone
27	* To meet the study requirements, patients must have at least one device.
28	To meet the study requirements, patients must have at least one device.
29	2 De ven have Internet access on your devices?
30 31	 Do you have Internet access on your devices? Yes
32	
33	- No
34	
35	* To meet the study requirements, only patients that answer YES could participate.
36 37	
38	3. How often do you use the Internet (including email)?
39	· Never
40	· Less than once a month
41	· Once a month
42 43	• Once or twice a week
43 44	· Everyday
45	
46	* To meet the study requirements, patients who check ONE OF THE FIRST TWO BOXES will
47	not be able to participate.
48	
49 50	4. When you are online, which of the following activities do you do? (check all that apply):
51	· I check the email
52	· Web surfing / Searching information
53	Shopping / User accounts payment
54	· I play video games
55 56	· I download or listen to music
57	· I watch videos or movies
58	· I use social networks (e.g. Facebook, Instagram, Twitter, Snapchat, Telegram,)
59	· I send instant messages (e.g. Skype, WhatsApp, Facebook Messenger, Telegram)
60	· I read press news

- · I take courses or distance studies
- · Use of different Apps

* To meet the study requirements, patients must check AT LEAST 3 BOXES to participate.

tor peet terien only

Additional file 3 - O'Halloran list

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
Α	A04	Weakness/Tiredness general	029	Chronic fatigue syndrome
			031	Myalgic encephalomyelitis
			030	Post viral fatigue syndrome
			028	Post viral syndrome
	A70	Tuberculosis	[
	A79	Malignancy, NOS		
	A90	Congenital anomaly NOS/multiple		
В	B72	Hodgkin's disease/lymphoma		
	B73	Leukaemia		
	B74	Malignant neoplasm blood other	\mathbf{C}	
	<i>B75</i>	Benign/unspecified neoplasm blood	008	Myelodysplastic syndrome
			004	Polycythaemia rubra vera
	B78	Hereditary haemolytic anaemia		
	B81	Anaemia, Vit B12/folate deficiency		
	B82	Anaemia, other/unspecified		
	B83	Purpura/coagulation defects		
	B90	HIV infection/AIDS		
D	D72	Viral hepatitis	003	Hepatitis B
			008	Hepatitis C
			009	Hepatitis D
	D74	Malignant neoplasm stomach	[
	D75	Malignant neoplasm colon/rectum		
	D76	Malignant neoplasm pancreas		

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
	D77	Malignant neoplasm digestive other/NOS		
	D81	Congenital anomaly digestive system	011	Atresia; biliary
			005	Cleft;palate/lip
			007	Disease;Hirschsprungs
			002	Harelip
			001	Megacolon;congenital
	D84	Congenital anomaly digestive system		
	D85	Duodenal ulcer		
	D86	Peptic ulcer other		
	D92	Diverticular disease		
	D93	Irritable bowel syndrome		
	D94	Chronic enteritis/ulcerative colitis	\mathbf{C}	
	D97	Liver disease NOS		
	D98	Cholecystitis/cholelithiasis		
	D99	Disease digestive system, other	029	Blind loop syndrome
			032	Insufficiency;pancreatic
			017	Insufficiency;vascul;mesentery
			013	Gluten sensitivity
			015	Intolerance;fat
			012	Intolerance;gluten
			054	Intolerance; lactose
			028	Malabsorption syndrome
			043	Pancreatitis
			036	Pyloric stenosis; acquired
			024	Sprue
			055	Stenosis;anal

 BMJ Open

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
			025	Stenosis;sigmoid colon
			016	Thrombosis;mesenteric
	F74	Neoplasm of eye/adnexa	003	Carcinoma;eye
			002	Neoplasm malig;eye
	F83	Retinopathy		
	F84	Macular degeneration		
	F92	Cataract		
	F93	Glaucoma		
	F94	Blindness		
Н	H75	Neoplasm of ear	003	Carcinoma;ear
			002	Neoplasm malig;ear
	H82	Vertiginous syndrome		•
	H84	Presbyacusis		
	H86	Deafness		
K	K71	Rheumatic fever/heart disease	010	Carditis;rheumatic;chronic
			012	Myocarditis;rheumatic;chronic
			015	Stenosis; arterial; rheumatic
			005	Stenosis;mitral;rheumatic
	K72	Neoplasm, cardiovascular	003	Carcinoma;cardiovascular
			002	Neoplasm malig;cardiovascular
	K73	Congenital anomaly, cardiovascular	Ι	
	K74	Ischaemic heart disease with angina		
	K75	Acute myocardial infarction		
	K76	Ischaemic heart disease without angina		
	K77	Heart failure		

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
	K78	Atrial fibrillation/flutter		
	K79	Paroxysmal tachycardia		
	K80	Cardiac arrhythmia NOS		
	K81	Heart/arterial murmur NOS		
	K82	Pulmonary heart disease		
	K83	Heart valve disease NOS		
	K84	Heart disease, other		
	K86	Hypertension, uncomplicated		
	K87	Hypertension, complicated		
	K88	Hypertension, complicated Postural hypotension Transient cerebral ischaemia		
	K89	Transient cerebral ischaemia		
	K90	Stroke/cerebrovascular accident	\mathbf{C}	
	K91	Cerebrovascular disease		
	K92	Atherosclerosis/peripheral vascular disease		
	К93	Pulmonary embolism		
	K94	Phlebitis/thrombophlebitis		
	K95	Varicose veins of leg		
L	L71	Malignant neoplasm, musculoskeletal		
	L82	Congenital anomaly, musculoskeletal	001	Achondroplastic dwarf
			003	Clubfoot
			015	Curvature of spine; congenital
			025	Deformity;foot;congenital
			024	Dislocation; hip; congenital
			013	Ehlers Danlos syndrome
			021	Kyphoscoliosis; congenital

 BMJ Open

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
			019	Kyphosis; congenital
			007	Lordosis;congenital
			018	Osteogenesis imperfecta
			027	Plagiocephaly
			012	Scoliosis; congenital
			014	Talipes
	L83	Neck syndrome		
	L84	Back syndrome without radiating pain		
	L85	Acquired deformity of spine		
	L86	Back syndrome with radiating pain		
	L88	Rheumatoid/seropositive arthritis		
	L89	Osteoarthritis of hip		
	L90	Osteoarthritis of knee		
	L91	Osteoarthritis, other		
	L92	Shoulder syndrome		
	L93	Tennis elbow		
	L95	Osteoporosis		
	L99	Musculoskeletal disease, other	047	Arthropathy; Behcets syndrome
			087	Arthropathy;Reiters disease
			088	Chondromalacia;patella
			013	Disease; Pagets (bone)
			093	Dystrophy;muscular
			056	Lupus erythematosus
			025	Osteitis
			026	Osteitis deformans
			060	Polymyositis

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
			071	Progressive system sclerosis
			075	Reiters syndrome
			078	Repetitive Strain Injury
			069	Scleroderma;diffuse
			070	Scleroderma;localised
			028	Scleroderma;progressive
			033	Sjorgens syndrome
			065	Systemic lupus erythematosus
N	N73	Neurological infection, other		
	N74	Malignant neoplasm nervous system		
	N75	Benign neoplasm nervous system		
	N76	Neoplasm nervous system, unspecified	\mathbf{C}	
	N85	Congenital anomaly neurological		
	N86	Multiple sclerosis		
	N87	Parkinsonism		
	N88	Epilepsy		
	N89	Migraine		
	N90	Cluster headache		
	N92	Trigeminal neuralgia		
	N93	Carpal tunnel syndrome		
	N94	Peripheral neuritis/neuropathy		
	N99	Neurological disease, other	025	Arachnoiditis
			005	Atrophy;cerebral
			004	Chorea; Huntingtons
			027	Degeneration;cerebral
			010	Disease; motor neuron

BMJ Open

1	
2	
3	
4 5	
6	
7	
8	
9 10	
11	
12	
13	
14 15	
15 16	
16 17	
18	
19 20	
21	
22	
23	
24 25	
26	
27	
28	
29 30	
31	
32	
33 34	
34 35	
36 37	
38 39	
40	
41	
42	
43 44	
44	
46	

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
			042	Encephalopathy
			043	Encephalopathy;Wernickes
			011	Myasthenia Gravis
			003	Palsy;cerebral
			022	Palsy; infantile spastic
			040	Palsy; spastic
			017	Paralysis; infantile spastic
		Chronic alcohol abuse	018	Paraplegia
			020	Quadriplegia
			030	Syringomyelia
Р	P15	Chronic alcohol abuse		
	P70	Dementia	\mathbf{N}	
	P71	Organic psychosis, other		
	P72	Schizophrenia		
	P73	Affective psychosis		
	P74	Anxiety disorder/anxiety state		
	P75	Somatisation disorder		
	P76	Depressive disorder		
	P78	Neuraesthenia, surmenage		
	P79	Phobia/compulsive disorder		
	P80	Personality disorder	ı	
	P81	Hyperkinetic disorder		
	P82	Post-traumatic stress disorder		
	P85	Mental retardation		
	P86	Anorexia nervosa/bulimia		
	P98	Psychosis NOS/other		

BMJ Open

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
	P99	Psychological disorders, other	005 006	Autism Autism;child
R	R84	Malignant neoplasm bronchus, lung		
	R85	Malignant neoplasm respiratory, other		
	R90	Hypertrophy tonsils/adenoids		
	R95	Chronic obstructive pulmonary disease		
	R96	Asthma		
	R99	Respiratory disease, other	015	Asbestosis
			018	Bronchiectasis
			004	Failure;respiratory
			009	Farmers lung
			019	Fibrosing alveolitis
			010	Fibrosis;pulmonary
			012	Pneumoconiosis
			020	Pneumonia; interstitial
S	S77	Malignant neoplasm of skin		
	S86	Dermatitis, seborrhoeic		
	S87	Dermatitis/atopic eczema		
	S91	Psoriasis		
	S96	Acne	007	Acne
			003	Acne;conglobulate (cystic)
			002	Acne;vulgaris
	S99	Skin disease, other	001	Acne;rosacea
			003	Dermatitis; herpetiformis
			034	Discoid lupus erythematosus
			042	Lichen sclerosus

 BMJ Open

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
			031	Necrobiosis lipoidica diabetic
			018	Pemphigus
			021	Rhinophyma
	T71	Malignant neoplasm thyroid		
	T73	Neoplasm endocrine other/uncertain	001	Carcinoma;endocrine
			002	Neoplasm malig;endocrine
	T80	Congenital anomaly endocrine/metabolic	007	Cretinism
			001	Disease;Hurlers
			002	Dwarfism
			005	Pseudohypoparathyroidism
	T81	Goitre		
	T82	Obesity	C1.	
	T83	Overweight		
	T85	Hyperthyroidism/thyrotoxicosis		
	T86	Hypothyroidism/myxoedema		
	Т89	Diabetes, insulin dependent		
	Т90	Diabetes, non-insulin dependent		
	Т92	Gout		
	Т93	Lipid disorder		
	T99	Endocrine/metabolic/nutritional disease, other	001	Acromegaly
			006	Amyloidosis
			028	Cushings syndrome
			053	Cystic fibrosis
			011	Diabetes insipidus
			002	Disease; Addisons

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
			064	Disease;fibrocystic
			013	Disease;Gilberts
			018	Disease;Hashimotos
			046	Disease; Wilsons
			035	Haemochromatosis
			073	Homocystinuria
			036	Hyperaldosteronism
			037	Hyperparathyroidim
			069	Hyperprolactinaema
			030	Hypoparathyroidism
			023	Phenylketonuria
			043	Polycystic ovary syndrome
			026	Porphyria
			040	Stein Leventhal syndrome
			041	Thyroiditis
U	U75	Malignant neoplasm kidney		
	U76	Malignant neoplasm bladder		
	U77	Malignant neoplasm, urinary, other		
	U88	Glomerulonephritis/nephrosis		
	U99	Urinary disease, other	019	Diverticulitis; bladder
			023	Failure;renal;chronic
			022	Insufficiency;renal
			006	Necrosis;renal
			024	Necrosis;renal;papillary
			013	Reflux; ureteric
			028	Stenosis; artery; renal

СНАР	ICPC-2 RUBRIC	DESCRIPTION	ICPC-2 PLUS CODE	DESCRIPTION
			017	Stenosis; urethral
W	W15	Infertility/subfertility		
	W72	Malignant neoplasm related to fertility		
X	X74	Pelvic inflammatory disease		
	X75	Malignant neoplasm cervix		
	X76	Malignant neoplasm breast female		
	X77	Malignant neoplasm genital female other		
	X99	Genital disease, other	016	Endometriosis
			009	Fistula;vaginal
Y	Y77	Malignant neoplasm prostate		
	Y78	Malignant neoplasm male genital, other		
	Y85	Benign prostatic hypertrophy		
				0

N.B. Italics indicate that the ICPC-2 rubric is chronic only at the ICPC-2 PLUS level. Conditions listed in the 'ICPC-2 PLUS Code' column are those within the rubric which

have been labelled as chronic using the extended terminology of ICPC-2 PLUS.

Source: O'Halloran J, Miller GC, Britt H. Defining chronic conditions for primary care with ICPC-2. Family Practice [Internet]. 2004 Aug 1;21(4):381-6.

Additional file 4 - Informed consent

Patient information sheet

Clinical trial

INTRODUCTION

Dear Sir or Madam,

We would like to inform you that we are implementing the clinical trial entitled "Effectiveness and cost-effectiveness of a virtual Community of Practice (CdPV web application) for improving the empowerment of middle-aged individuals with multimorbidity: RCT".

This is a multicenter project involving Madrid: PI22/01124, the project coordinator, and the Canary Islands: PI22/00691.

This study has been approved by the Ethics Committees for Clinical Research of the participating centers in accordance with current legislation, Organic Law 3/2018, of December 5, on the Protection of Personal Data and the Guarantee of Digital Rights, and the application of Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016. Here you will find the correct and sufficient information to evaluate and decide whether or not you want to participate in this study. To do so, please read this information sheet carefully, and we will clarify any doubts that may arise after the explanation. Furthermore, you may consult with anyone you deem appropriate.

Voluntary participation

You should be aware that your participation in this study is voluntary, and you have the right to choose not to participate or change your decision and withdraw your consent at any time. Your decision will not affect your relationship with your doctor, nor will it cause any harm to your treatment.

Who are the researchers?

 The research team is a multidisciplinary group of professionals, including medical doctors, psychologists, statisticians, healthcare service evaluators, general practitioners, nurses, and cardiologists. The team members are affiliated with the following institutions: Avedis Donabedian Foundation, Primary Care Management, and the Directorate General of Research, Teaching, and Innovation of the Ministry of Health of the Community of Madrid, as well as the Service for the Evaluation of the Canary Islands Health Service (SESCS).

STUDY DESCRIPTION

Why is this study being conducted?

The purpose of this study is to evaluate the effectiveness of a virtual Community of Practice (VCoP) for middle-aged individuals with multiple chronic diseases. We aim to improve their knowledge, skills, and self-confidence in managing their own health. This will be measured using the specific Patient Activation Measure (PAM) questionnaire, which assesses activation levels in individuals with chronic diseases, at 12-months, comparing it with the active control group.

Who can participate?

If you are between 30 and 60 years old, have been diagnosed with two or more chronic diseases, and have internet access at home and/or a smartphone, you are eligible to participate.

Study procedure:

There will be two study groups: the Intervention Group (GI) and the Control Group (GC). Participants will be randomly assigned to one of these groups. If you decide to participate in the study, you could be placed in either group.

If you choose to participate, what does your involvement entail?

BMJ Open

 The study will last for 18 months. At the beginning of the study and at 6, 12, and 18 months, participants will complete online questionnaires. These questionnaires will assess various aspects related to each participant's level of activation in health-related decisions (PAM questionnaire), depression using the self-administered Patient Health Questionnaire-9 (PHQ-9), anxiety using the self-administered Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A), treatment burden using the self-administered Treatment Burden Questionnaire (TBQ), and health-related quality of life using the self-administered E5-5D-5L questionnaire (EuroQol group). Completing these questionnaires will take approximately 30 minutes.

During the baseline visit, sociodemographic variables and other variables related to your chronic diseases and treatment will be collected. If necessary, access to your medical history may be granted to verify this information.

If you are randomly assigned to the IG, you will be offered the opportunity to participate for 18 months in a Virtual Community of Practice (VCoP) based on a web 2.0 platform. A registration link will be provided to you via email to initiate your voluntary participation.

In the Virtual Community of Practice (VCoP), you will have access to leisure and educational activities based on strategies that facilitate learning, as well as the exchange of knowledge and experiences among participants and a multidisciplinary team of professionals. Various topics related to health competencies, self-efficacy techniques, lifestyle, acceptance of chronic illness, and shared decision-making will be addressed. If you are randomly assigned to the CG, you will continue to receive the standard care and attention provided in regular clinical practice. Additionally, you will be offered the same educational content as the intervention group but self-administered.

Benefits and risk of participating in this study.

BMJ Open

There are no anticipated physical or psychological risks associated with participating in this study. The main benefit for participants with multiple chronic diseases is the opportunity to improve their knowledge, skills, and self-confidence in managing their own health and healthcare.

Confidentiality

The processing, communication, and transfer of personal data of all participating individuals will comply with the provisions of Organic Law 3/2018, of December 5, on the Protection of Personal Data and Guarantee of Digital Rights, and the application of Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016, on the Protection of Personal Data (GDPR). It is important that you are aware of the following information:

In addition to the rights, you are already familiar with (access, modification, objection, and cancellation of data), you now also have the right to limit the processing of incorrect data, request a copy of the data you have provided for the study, or have them transferred to a third party (data portability). Similarly, you have the right to withdraw your consent for data processing; however, such withdrawal may result in your discontinuation of participation in the trial. To exercise your rights, please contact the principal investigator of the study. Please note that data cannot be deleted even if you discontinue participation in the trial or withdraw your consent for data processing, to ensure the validity of the research and comply with legal obligations and medication authorization requirements. You also have the right to file a complaint with the Data Protection Agency if you are not satisfied.

Altogether, the Center, the Sponsor, and the Investigator are each responsible for your data processing and are committed to comply with current data protection regulations. The data collected for the study will be identified using a code, so that no information

that can identify you is included. Only your study doctor/collaborators will be able to link this data to you and your medical history. Therefore, your identity will not be disclosed to anyone else unless required by health authorities or in cases of medical emergency. The Research Ethics Committees, representatives of the Health Authority responsible for inspection, and authorized personnel from the Sponsor may access personal data to verify the study procedures and compliance with good clinical practice standards (always maintaining the confidentiality of the information).

The Investigator and the Sponsor are obligated to retain the data collected for the study for at least 25 years after its completion. Afterwards, your personal information will only be retained by the healthcare center for your health care purposes and by the Sponsor for other scientific research purposes if you have provided consent for such retention, and if allowed by law and applicable ethical requirements.

Additional information

As required by law, you will need to sign and date the informed consent document to participate.
Project coordinator. Principal investigator. (Madrid):

Ana Isabel González González.

Innovation and International Projects Unit.

Subdirección General de Investigación, Docencia e Innovación. Consejería de Sanidad

de la Comunidad de Madrid.

contact: aisabel.gonzalezg@salud.madrid.org

Principal investigator (CANARIAS):

1	
2	
3	Lilisbeth Perestelo Pérez, Servicio de Evaluación del Servicio Canario de la Salud
4 5	
6	Contact: lperperr@gobiernodecanarias.org
7	
8	
9	
10	
11	
12	
13	
14	
15 16	
17	
18	
19	
20	
21	
22	
23	
24	
25 26	
20	
28	
29	
30	
31	
32	
33	
34	
35 36	
37	
38	
39	
40	
41	
42	
43 44	
44 45	
46	
47	
48	
49	
50	
51	
52 53	
53 54	
55	
56	
57	
58	
59	
60	

Informed consent for patients

(name and surname) declares:

That I have read the Patient information sheet.

That I could make any questions regarding the study

That I have enough information about the study

I received this information from:

I understand that my participation is volunteer, and I can withdraw it:

- 1. Whenever I want.
- 2. I don't have to give any explanations.

3. Without any repercussions for my healthcare.

- I freely give my consent to participate in the study and authorize the access and use of

my data under the conditions detailed in the information sheet.

Name of the participant:

Date:

Signature:

Investigator name:

Date:

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Signature:

to peet terier only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

DICTAMEN DEL COMITÉ de ÉTICA DE LA INVESTIGACIÓN con MEDICAMENTOS

D. Roberto Collado Borrell, Secretario Técnico del COMITÉ de ÉTICA DE LA INVESTIGACIÓN con MEDICAMENTOS HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN

CERTIFICA

Que se ha evaluado la propuesta del promotor referida al estudio observacional:

Código PI22/01124

1 2

3

4

5 6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21 22

23

24

25

26 27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56 57 TÍTULO: "Efectividad y coste-efectividad de una Comunidad de Práctica virtual (CdPV aplicación web) para la mejora del empoderamiento de personas de mediana edad con multimorbilidad: ECA"

Protocolo versión 2. 29 de mayo de 2023. Hoja de Información al paciente y Consentimiento Informado Fase Ensayo Clínico versión 3. 7 de junio de 2023. Hoja de Información al paciente y Consentimiento Informado Fase Co-Diseño versión 1. 20 de marzo de 2023.

Promotor: Investigador

- El estudio se plantea siguiendo los requisitos legalmente establecidos, y su realización es pertinente.
- Se cumplen los requisitos necesarios de idoneidad del protocolo en relación con los objetivos del estudio y están justificados los riesgos y molestias previsibles para el sujeto.
- Es adecuado el procedimiento para obtener el consentimiento informado
- El alcance de las compensaciones económicas previstas no interfiere con el respeto a los postulados éticos.
- La capacidad del investigador y sus colaboradores, y las instalaciones y medios disponibles, tal y como ha sido informado, son apropiados para llevar a cabo el estudio.

Este CEIm actuando como comité evaluador, emite dictamen favorable y acepta que dicho estudio sea realizado en los centros siguientes por los investigadores principales que se relacionan a continuación:

Dra. Ana Isabel González González / Unidad de Innovación y Proyectos Internacionales - Consejería de Sanidad de la Comunidad de Madrid

Y HACE CONSTAR QUE:

1º En la reunión celebrada el día 05 de junio de 2023, acta 11/2023 se decidió emitir el informe correspondiente al estudio de referencia.

2° En dicha reunión se cumplieron los requisitos establecidos en la legislación vigente -Real Decreto 1090/2015 y Decreto 39/94 de la Comunidad de Madrid- para que la decisión del citado CEIm sea válida.

3º El CEIm, tanto en su composición, como en los PNT cumple con las normas de BPC (CPMP/ ICH/ 135/95)

4º La composición actual del CEIm es la siguiente:

D. ANDRÉS JESÚS MUÑOZ MARTÍN (Oncología Médica - Presidente) Dª. MARÍA LUISA NAVARRO GÓMEZ (Pediatría - Vicepresidenta) D. ROBERTO COLLADO BORRELL (Farmacia Hospitalaria - Secretario Técnico) D. JUAN ANTONIO ANDUEZA LILLO (Medicina Interna) D^a. BEATRIZ AUDIBERT AMOROTO (Licenciada en Derecho) D^a. MARÍA LUISA BAEZA OCHOA DE OCÁRIZ (Alergología) D^a. PILAR AITANA CALVO FERRÁNDIZ (Farmacología Clínica) D^a. ISABEL CASTREJÓN FERNÁNDEZ (Reumatología) D^a MARÍA DEL CARMEN DE LA CRUZ ARGUEDAS (Unidad de Apoyo a la Investigación) D. VICENTE DE LAS PEÑAS GIL (Psicología Clínica) D. JAVIER DE MIGUEL DÍEZ (Neumología) D^a. PATRICIA FONT LÓPEZ (Hematología y Hemoterapia) D^a. ISABEL GÓMEZ VALBUENA (Farmacia de Atención Primaria) D. PABLO GONZÁLEZ NAVARRO (Bioestad'sitica) D^a. MARÍA DEL CARMEN HERAS ESCOBAR (Enfermería) D^a. LUIS IBÁÑEZ SAMANIEGO (Digestivo) D^a. ANA MARÍA IGLESIAS MOHEDANO (Neurología) D. LUIS ANDRÉS LÓPEZ FERNÁNDEZ (Biología) D^a. ANA ESTHER LÓPEZ PÉREZ (Anestesiología v Reanimación) D. ANTONIO MUIÑO MIGUEZ (Medicina Interna) D^a. SARA PÉREZ RAMÍREZ (Oncología) D. JOSÉ LUIS REVUELTA HERRERO (Farmacia Hospitalaria) D. EDUARDO ZATARAÍN NICOLÁS (Cardiología) Lo que firmo en Madrid, a 07 de junio de 2023

Page 59 of 59





El estudio de investigación titulado: "Efectividad y coste-efectividad de una Comunidad de Práctica Virtual (CdPV aplicación web) para la mejora del empoderamiento de personas de mediana edad con multicomorbilidad: ECA", versión 1_19012023, con código CHUNSC_2023_06, del que es Investigador Principal la Dra. LILISBETH PERESTELO PEREZ, ha sido evaluado por el Comité de Ética de la Investigación con medicamentos del Complejo Hospitalario Universitario de Canarias (Provincia de Santa Cruz de Tenerife) en su sesión del 26/01/2023, y considera que:


Se cumplen los requisitos necesarios de idoneidad del Protocolo con los objetivos del estudio.

El procedimiento para obtener el consentimiento informado, incluyendo la hoja de información para los sujetos y el consentimiento informado, **versión 2, 13-03-2023** y la hoja de información al profesional y el consentimiento informado, **versión 2, 13-02-2023**, es adecuado.

La capacidad del Investigador y los medios disponibles son adecuados para llevar a cabo el estudio y no interfiere con el respeto a los postulados éticos.

Por todo ello, el Comité de Ética de la Investigación con medicamentos del Complejo Hospitalario Universitario de Canarias (Provincia de Santa Cruz de Tenerife) emite dictamen **FAVORABLE** para la realización de este estudio en el Servicio de Evaluación del Servicio Canario de la Salud (SESCS).

Secretario Técnico en funciones del CEIm Complejo Hospitalario Universitario de Canarias









INFORMACIÓN ADICIONAL:

BMJ Open

Es responsabilidad del investigador principal garantizar que todos los investigadores asociados con este proyecto conozcan las condiciones de aprobación y los documentos aprobados.

El Investigador Principal debe informar a la Secretaría del CEIm mediante una enmienda, informe anual de seguimiento o notificación, de:

• Cualquier cambio significativo en el proyecto y la razón de ese cambio, incluida una indicación de las implicaciones éticas (si las hubiera);

- Eventos adversos graves en los participantes y la acción tomada para abordar esos efectos;
- Cualquier otro evento imprevisto o inesperado, como desviaciones de protocolo;
 - El cambio de Investigador Principal;
 - Informe anual de seguimiento;
 - La fecha de finalización del estudio;
 - Informe final del estudio y/o publicación de resultados.

Este documento ha sido firmado electrónicamente por: FERNANDO ALBERTO HIDALGO FIGUEROLA - FEA FARMACOLOGIA CLINICA

En la dirección https://sede.gobiernodecanarias.org/sede/verifica_doc?codigo_nde= puede ser comprobada la autenticidad de esta copia, mediante el número de documento electrónico siguiente: 0zDFQeTx3noGFkthCAAhjo43Y50CcLPRp FOr peer review only - http://br

El presente documento ha sido descargado el 15/02/2023 - 14:37:59



Fecha: 15/02/2023 - 14:02:24